

Index

- 5% serum albumin in saline 261–262
- A antigen 81
- A-transferase (GTA) 81, 83–84
- AABB *see* Association for the
Advancement of Blood and
Biotherapies
- AAV *see* ANCA-associated vasculitis
- ABC transporters 116
- ABC/EBA *see* America's Blood Centers/
European Blood Alliance
- ABCC1 blood group system 117
- ABCC4 116–117
- ABH antibodies 82, 87
- ABH system *see* ABO system
- abnormal clotting tests absent of bleeding,
prophylactic plasma 213–214
- ABO antibody titers 38–39
- ABO gene 83–84
- ABO system 81–87, 330
- antibodies 82
- biological roles 86–87
- biosynthesis 81–82
- chemistry 81–82
- coagulation 86
- donor testing 37–39, **38**
- epitopes 81–82
- expression 81–82, 84, 85
- hemolytic disease of the fetus and
newborn 85, 364–365
- innate immunity 87
- molecular biology 83–85
- platelets 170–171, 484
- secretor-positive individuals 81–82
- serology 82
- solid organ transplantation 85
- stem cell transplantation 85–86
- tissue-specific regulation 84
- transfusion considerations 85
- weak subtypes 82–83
- ABO typing
- donors 37–39, **38**
- hematopoietic stem cells 620
- human tissue allografts 672–673
- plasma composition 202
- recipients 124
- absent iron stores (AIS) 57
- absenteeism, health emergencies 16
- absolute neutrophil count (ANC) 190–191
- accreditation, hospital transfusion
services 73
- ACE *see* angiotensin-converting enzyme
- acellular dermal matrix 675
- acellular therapy, renal failure 655
- acid–citrate–dextrose (ACD)
solutions 8–9, 151, 152
- acidified serum test (HAM test) 360
- ACKR1 *see* atypical chemokine receptor 1
- acquired bleeding disorders 443–452
- acquired immune deficiency syndrome
(AIDS)
- initial cases 10
- nucleic acid tests 31
- see also* human immunodeficiency virus
- acquired von Willebrand disease (AVWS)
451–452
- ACS *see* acute chest syndrome
- ACT *see* activated clotting time
- actin, megakaryocytes 160, 161
- actin depolymerizing factor (ADF) 161
- activated clotting time (ACT),
intraoperative use 459
- activated partial thromboplastin time
(aPTT) 205–207, 457–458
- activated prothrombin complex
concentrate (aPCC) 444–445
- adverse reactions 445
- dosing 445
- indications 444
- purification 227–228
- storage 444
- activin receptor ligand traps 606
- acute adverse reactions
- apheresis 264–266
- blood collection 49–55
- air embolism 54, 258
- allergic 258
- apheresis 53–55, 256–258
- automated component collections 53
- citrate reactions 53–54
- citrate toxicity 257
- delayed 50
- donation frequency 54
- granulocyte collection 54–55
- hypotension 257
- immediate 50
- multiple component collection 54
- phlebotomy-related 52–53
- phlebotomy-related nerve injury 53
- presyncopal 50, 257
- risk factors 51, 53
- syncopal 51–52
- therapeutic plasma exchange 264–266
- acute autoimmune diseases,
immunoglobulin therapy 245–246
- acute chest syndrome (ACS), red cell
exchange 279, 333
- acute disseminated encephalomyelitis
(ADEM), apheresis 268
- acute hemolytic transfusion reactions
(AHTR) 543–552
- see also* hemolytic transfusion reactions
- acute inflammatory diseases,
immunoglobulin therapy 245–246
- acute lung injury *see* transfusion-related
acute lung injury
- acute multiorgan failure syndrome, red cell
exchange 279–280
- acute myeloid leukemia, myeloid growth
factors 610
- acute myocardial infarction, red blood cell
administration 321–322
- acute nonvolumic hemodilution (ANH)
301–302, 462, 484
- acute phase reaction, plasma
composition 202
- acute radiation syndrome, myeloid growth
factors 611
- acute splenic sequestration crisis
(ASSC) 334
- acute stroke
- red cell exchange 279
- sickle cell disease 332
- N-acylsphingosine 93
- adaptive mechanisms, anemia 316
- additive solutions
- platelets 184–185
- red blood cells 152–154

- ADEM *see* acute disseminated encephalomyelitis
 adenosine 5'-triphosphate (ATP)
 platelets 181
 red blood cells 143, 145, 147–148, 151, 156
 adenosine diphosphate (ADP) 145
 adenosine monophosphate (AMP) 147–148
 ADF *see* actin depolymerizing factor
 administration
 acute nonvolemia hemodilution 301–302, 462, 484
 bedside pumps 313
 blood avoidance techniques 461–462
 blood group considerations
 ABO system 85
 Diego system 114
 Duffy protein 113
 I blood group 92
 Kell blood group 112
 Kidd system 113–114
 Lewis blood group 89
 MNS blood group 111
 P blood group 96
 Rh system 106–107
 Sd^a antigen 97
 blood warming 313
 burn patients 478–481
 coagulation factor replacement 424–452
 component issue and release 307
 component modifications 309–310
 component preparation 309–311
 conservative practice 461
 cryoprecipitate 210–211, 214–215
 burn patients 480
 children 390–391
 hemophilia 426–427
 trauma patients 480
 donor screening 31–32
 factor VIII 427
 fetal 379–380, 420–421
 gene therapy 642–643
 granulocytes 195–198, 487
 hematopoietic stem cells 622
 hemovigilance 503–506
 hospital tissue services 679
 immunoglobulin G 240–248
 infusion flow rates 312
 intravenous immunoglobulin 241–248
 adverse reactions 242–243
 autoimmune mucocutaneous bullous diseases 247
 chronic inflammatory demyelinating polyradiculoneuropathy 246
 drug interactions 241
 Guillain-Barré syndrome 245–246
 hemolytic disease of the fetus and newborn 370
 heparin-induced thrombocytopenia 414–415
 high-dose therapy 241
 hyperimmune globulins 247–248
 immune thrombocytopenic purpura 246, 407–408
 Kawasaki disease 245
 multifocal motor neuropathy 246–247
 neonatal alloimmune thrombocytopenia 420
 oncology patients 486
 posttransfusion purpura 421
 primary immune deficiencies 244–245
 secondary immune deficiencies 245
 transplantation 247
 vaccine-induced immune thrombotic thrombocytopenia 417
 warm autoimmune hemolytic anemia 350
 obstetrics 375–380
 perioperative practice 453–470
 plasma 209–215
 adverse reactions 215
 angiography 468–469
 bleeding treatment 212–213
 bronchoscopy 468
 burn patients 480
 central venous catheter insertions 466–467
 children 388–390
 clinical use 212
 combined factor V and factor VIII deficiency 438
 cryoprecipitate 214–215
 disseminated intravascular coagulation 213
 epidural anesthesia 468
 factor V deficiency 438
 hemolytic disease of the fetus and newborn 370–371
 hemophilia 426–427
 infants 388–390
 liver biopsy 467
 lumbar puncture 468
 neurosurgical procedures 468
 oncology patients 486
 paracentesis 468
 perioperative guidelines 464–466
 prophylactic 213–214
 prothrombin deficiency 437
 thoracentesis 468
 transbronchial lung biopsy 468
 trauma patients 480
 upper airway procedures 468
 platelets 395–400
 bronchoscopy 469
 cardiac surgery 470
 central venous catheter placement 469
 children 385–388
 dosing 397
 epidural anesthesia 470
 fetal 379
 infants 385–388
 liver biopsy 469
 lumbar puncture 470
 maternal 378
 neurosurgical procedures 470
 oncology patients 484–486
 paracentesis 469
 perioperative guidelines 464–466
 preoperative 397–398
 prophylactic 396–397
 refractoriness 398–399, 422
 therapeutic 398–400
 thoracentesis 469
 transbronchial lung biopsy 469
 upper airway procedures 469
 pretransfusion considerations 306–307
 prophylactic
 granulocytes 198
 hemophilia 427
 plasma 213–214
 platelets 396–397
 rapid infusion practices 313–314
 recipient management 129
 red blood cells
 acute myocardial infarction 321–322
 cardiac surgery 319–321
 children 322, 381–385
 chronic anemia 324
 clinical trials 318–332
 cold agglutinin disease 354
 complications 342–345
 critical care 319
 decision-making 323
 dosing 324
 fetal 379
 guidelines 322–324
 hemolytic disease of the fetus and newborn 370–371
 infants 381–385
 maternal 378
 microcirculatory effects 316–317
 monitoring 341–342
 oncology patients 322, 482–484
 orthopedic surgery 321
 paroxysmal cold hemoglobinuria 355
 paroxysmal nocturnal hemoglobinuria 362–363
 perioperative guidelines 464–466
 preterm infants 382–383
 protocols 339–341
 sickle cell disease 331–335, 332
 surgical outcomes 455–457
 targets 341–342
 transfusion thresholds 324
 upper gastrointestinal bleeding 321
 warm autoimmune hemolytic anemia 350–351
 Rh immune globulin 408
 sets and filters 311

- administration (*cont'd*)
 - transfusions 311–313
 - trauma patients 471–478, 479–481
 - venipuncture 307
 - whole blood 480
- ADP *see* adenosine diphosphate
- adult neutropenias 192–193
- adverse sequelae
 - activated prothrombin complex
 - concentrate 445
 - acute lung injury 569–579
 - allergic responses 558–561, 580
 - anaphylaxis 559–561
 - andexanet alfa 450
 - antifibrinolytics 448
 - apheresis 264–266
 - bacterial contamination 46, 487, 533–542
 - blood collection 49–55
 - air embolism 54, 258
 - apheresis 53–55, 256–258
 - automated component collections 53
 - citrate reactions 53–54
 - delayed 50
 - donation frequency 54
 - granulocyte collection 54–55
 - hypotension 257
 - immediate 50
 - multiple component collection 54
 - phlebotomy-related 52–53
 - phlebotomy-related nerve injury 53
 - presyncopal 50, 257
 - risk factors 51, 53
 - syncopal 51–52
 - children 388
 - chimeric antigen receptor T-cell
 - therapy 488
 - circulatory overload 563–564, 579–580
 - citrate toxicity 257, 561–562
 - cryoprecipitate transfusion 215
 - desmopressin 448–449
 - dimethyl sulfoxide toxicity 565–566
 - dyspnea 580
 - electrolyte disorders 562–563
 - erythroid growth factors 604–605
 - febrile nonhemolytic transfusion
 - reactions 553–558
 - gene therapy 644
 - hematopoietic progenitor cells 487–488
 - hemolytic transfusion reactions 242–243, 543–552
 - hemovigilance 503–506
 - hypothermia 563
 - idarucizumab 450
 - immunoglobulin transfusion 242–243
 - iron overload 281, 344–345, 587–597
 - massive transfusion protocols 561–564
 - microaggregate debris 563
 - myeloid growth factors 608–609
 - nonhemolytic transfusion reactions 553–568
 - oncology patients 487–488
 - parasite infections 523–529
 - plasma transfusion 215
 - plastizer toxicity 565
 - prion transmission 529–531
 - protamine 449
 - prothrombin complex concentrates 444
 - rapid infusion practices 561–564
 - recombinant activated factor VII 445–446
 - red blood cell transfusion 342–345
 - reporting 503–506
 - respiratory 569–580
 - therapeutic plasma exchange 264–266
 - thrombopoietic growth factors 613–614
 - transfusion-associated graft-versus-host
 - disease 582–586
 - transfusions, reporting 70–73, 129–130
 - viral infections 507–522
 - vitamin K 447
 - see also* acute adverse reactions; chronic effects
- AF *see* atrial fibrillation
- affinity maturation 119–120
- afibrinogenemia 441
- A4GALT1 94, 95
- age, plasma composition 202
- agglutination
 - blood groups discovery 7
 - mechanism 120–122
- AHF *see* antihemophilic factor
- AHG *see* antihuman globulin
- aHUS *see* atypical hemolytic-uremic syndrome
- AIDS *see* acquired immune deficiency syndrome
- AIHA *see* autoantibody hemolytic anemia
- AIM-1 kinase (Aurora-B kinase) 159
- air embolism, apheresis 54, 258
- AIS *see* absent iron stores
- alanine transferase (ALT) 506
- albumin 200
 - pathogen reduction 496
- alemtuzumab, warm autoimmune hemolytic anemia 350
- aliquoting 310
- allergic responses, apheresis 54, 258, 264
- allergic transfusion reactions (ATR)
 - diagnosis 558–559
 - prevention 559
 - transfusions 558–561
 - treatment 559
- allergic transfusion reactions (ATRs) 580
- allografts 670–683
 - ABO typing 672–673
 - acellular dermal matrix 675
 - adverse event monitoring 682
 - bone 673–674
 - cardiac 676–677
 - rejection, extracorporeal photopheresis 287–288
 - connective tissues 674–675
 - donation tracking 678–679
 - donor–recipient matching 672–673
 - extraembryonic tissue 677
 - hospital-based tissue services 679
 - human tissue 670–683
 - lung, rejection, extracorporeal photopheresis 288
 - ocular tissue 675–676
 - oversight 677–678
 - peripheral nerves 677
 - recalls and lookback 682–683
 - reimbursement 683
 - rejection, extracorporeal photopheresis 287–288
 - skin 675
 - surveillance 680–682
 - tissue processing 680
 - vascular tissue 676–677
- alloimmune thrombocytopenia 417–422
 - neonatal 395, 419–421
 - passive 421–422
 - post-transfusion purpura 421
 - transplantation-associated 422
- alloimmunization
 - febrile nonhemolytic reactions 555
 - granulocytes 487
 - pathogen reduction 498–499
 - platelets 171–177, 399–400, 485, 498–499
 - red blood cells 342–343, 483
- alpha thalassemia 328, 337
- alpha-1 antitrypsin 201
- alpha₁-proteinase inhibitor (API), purification 228
- alphaviruses 518
- ALT *see* alanine transferase
- altered CE phenotype 103–104
- Alyx instrument 253
- amotosalen/UV-A pathogen reduction 490, 492, 495, 497, 498, 499
- American Association of Blood Banks *see* Association for the Advancement of Blood and Biotherapies
- America's Blood Centers/European Blood Alliance (ABC/EBA) 77–78
- ε-aminocaproic acid (EACA) 447–448
 - surgical patients 462
- ammonia transport 105
- AMP *see* adenosine monophosphate
- AMR *see* antibody-mediated rejection
- amustaline/glutathione pathogen
 - reduction 492–493, 496, 499–500
- anamnesic response 119
- anaphylaxis
 - apheresis 258, 265
 - diagnosis 560
 - etiology 559–560
 - prevention 561
 - transfusions 559–561
 - treatment 560–561

- ANC *see* absolute neutrophil count
- ANCA-associated vasculitis (AAV) 272
- andexanet alfa 449–450
- anemia 314–326
- adaptive mechanisms 316
 - automimmune hemolytic 346–358
 - biochemistry 138–141
 - children 383
 - chronic 324, 375
 - chronic inflammation 141
 - clinical outcomes 317–319
 - cobalamin deficiency 138–140
 - definition 297
 - folate deficiency 138–140
 - hemolytic disease of the fetus and newborn 371
 - infants 381–382
 - macrocytic 138–140
 - microcytic 56–64, 140–141
 - neurocognitive effects 60
 - pathophysiological interactions 137
 - perioperative practice 453–455
 - pica 60–61
 - postpartum 377–378
 - pregnancy 373–375
 - preoperative management 297–299, 454–455
 - restless legs syndrome 60
 - risk factors 317–319
 - surgical outcomes 454
 - thalassemia 141
 - therapeutic plasma exchange 271
 - warm autoimmune hemolytic 106–107, 346–351
- anesthesia
- epidural
 - plasma administration 468
 - platelet administration 470
- angiography, plasma
 - administration 468–469
- angiotensin-converting enzyme (ACE)
 - inhibitors 265
- ANH *see* acute nonvolemia hemodilution
- animal transfusions 4
- animal-to-human transfusions 4–5, 7
- anti-HBc antibody testing 44
- antibodies
 - affinity maturation 119–120
 - blood groups 120–122, **121**
 - antigen interactions 120–122
 - physical properties 120
 - heavy chains 119
 - light chains 119
 - molecular structure 118–119, 120
 - Rh system 106, 107
 - thrombopoietic growth factors 614
 - transfusion-related acute lung injury 571, 574–576, 578
- antibody testing
 - Chagas' disease
 - CMV 46
- HBV 44
- HCV 44
- HIV 43
- HLA 47
- human leukocyte antigens 630–632
- human T-cell lymphotropic virus 44
- identification principles 126–127
- IgA deficiency screening 47
- platelets 47
- red blood cell antigens 38–39
- syphilis 4–6
- transfusion-related acute lung injury 578
- antibody titers
 - ABO system 38–39
 - IgA deficiency screening 47
- antibody-mediated rejection (AMR) 274
- antibody-specific prediction (ASP) 173–174
- anticoagulant-nutrient solutions, red blood cells 152
- anticoagulants
 - acid-citrate-dextrose solutions, development 8–9
 - apheresis 251–252
 - Braxton-Hicks 6–7
 - paroxysmal nocturnal hemoglobinuria 360
 - perioperative practice 459–461
 - twentieth century development 8–9
- antifibrinolytics 303, 447–448
- adverse reactions 448
- dosing 448
- hemophilia 432
- indications 447–448
- manufacturing 447
- obstetrics 377
- storage 447
- antigen receptors 118
- antigen testing
 - ABO typing 37–39, **38**
 - HLA 47
 - RBC extended 47
 - Rh typing 37–38
- antigen-presenting cells (APCs) 119
- antigens
 - ABCC1 system 117
 - ABO system 81–84
 - AUG system 117
 - Cartwright system 115
 - Chido/Rogers system 115
 - Colton system 114–115
 - CTL2 system 117
 - Diego system 114
 - Dombrock system 115–116
 - Gerbich system 115
 - GIL system 114–115
 - human leukocyte antigens 168–169, 625, 628
 - human platelet antigens 169–170
 - I blood group 90–92
- Indian system 115
- JR system 116
- Kell blood group 112–113
- Kidd system 113–114
- Knops system 115
- LAN system 116
- Lewis blood group 87
- Lutheran blood group 111
- LW system 107
- MAM system 117
- MNS blood group 109–111
- OK system 116
- P blood group system 93–94
- PEL system 116–117
- platelets 168–171
- RAPH system 116
- Scianna system 114
- Vel system 117
- antiglobulin tests 122, 124–125, 129
- antihemophilic factor (AHF) 486
- antihuman globulin (AHG) reagent 122
- antineutrophil cytoplasmic antibodies *see* ANCA
- antiphospholipid antibody syndrome (APS), pregnancy 375
- antiplatelet therapies, perioperative 459–461
- antiretroviral therapy (ART) 516
- antithrombin III, purification 230
- aPCC *see* activated prothrombin complex concentrate
- APCs *see* antigen-presenting cells
- apheresis 249–289
 - 5% serum albumin in saline 261–262
 - acute adverse reactions 53–55, 256–258, 264–266
 - acute disseminated encephalomyelitis 268
 - air embolism 54, 258
 - allergic responses 54, 258
 - allograft rejection 287–288
 - ANCA-associated vasculitis 272
 - angiotensin-converting enzyme inhibitors 265
 - antibody-mediated rejection 274
 - anticoagulants 251–252
 - autoantibody hemolytic anemia 271
 - babesiosis 282
 - bacterial contamination 536
 - biochemical changes 263–264
 - blood donation 252–258
 - catastrophic antiphospholipid syndrome 271
 - children 266
 - chronic effects 63–64
 - chronic inflammatory demyelinating polyradiculoneuropathy 267
 - citrate toxicity 257, 266
 - complement-mediated thrombotic microangiopathy 270
 - complications 256–258, 264–266

- apheresis (*cont'd*)
- component separation 251
 - continuous renal replacement therapy 263
 - cryoglobulinemia 271–272
 - cryoprecipitate 262–263
 - cutaneous T-cell lymphoma 287
 - desensitization in transplant recipients 274
 - dilated cardiomyopathy 275–276
 - donor collection 33–34
 - erythrocytapheresis 282–285
 - essential thrombocythemia 285–286
 - exchange volumes 260–261
 - extracorporeal membrane oxygenation 263
 - extracorporeal photopheresis 287–289
 - familial hypercholesteremia 276
 - ferritin monitoring 63
 - focal segmental glomerulosclerosis 272–273
 - fraction of the preprocedure cells remaining 278–279
 - fresh frozen plasma 262–263
 - Goodpasture syndrome 272
 - graft-versus-host disease 288–289
 - granulocyte collection 54–55, 195
 - Guillain-Barré syndrome 261, 266–267
 - Hashimoto's encephalopathy 269
 - hematologic disorders 269–272
 - hydroxyethyl starch 263
 - hypergammaglobulinemia 270–271
 - hyperleukocytosis 286
 - hypotension 257
 - immunoadsorption 275–276
 - immunoglobulin G 260–261
 - instrumentation 253–254, 259–260
 - iron overload prevention 281
 - Lambert-Eaton myasthenic syndrome 268
 - LDL removal 276
 - loiasis 289
 - malaria 281–282
 - N-methyl-D-aspartate receptor antibody encephalitis 267
 - multicomponent collections 253, 256
 - multiple sclerosis 268
 - mushroom poisoning 273
 - myasthenia gravis 267
 - myeloma cast nephropathy 273
 - neurological disorders 266–269
 - neuromyelitis optica spectrum disorder 268–269
 - nonhematopoietic cells 289
 - oral calcium supplementation 54
 - overdose 273
 - PANDAS 269
 - paraproteinemic demyelinating polyneuropathies 268
 - phytanic acid storage disease 269
 - plasma collection 254–255
 - platelet collection 255–256
 - pregnancy 281
 - principles 251–258
 - procedure requirements 254–256
 - product requirements 254–256
 - red cell exchange 278–282
 - rejection of transplants 274
 - replacement solutions 261–263, 265
 - secondary erythrocytosis 283–284
 - sickle cell disease 279–281
 - systemic lupus erythematosus 273
 - techniques 259–263
 - therapeutic phlebotomy 278, 282–285
 - therapeutic plasma exchange 251–252, 259–277
 - thrombocytosis 285–286
 - thrombotic microangiopathies 269–271
 - thrombotic thrombocytopenic purpura 261, 263, 270
 - thyroid storm 273
 - ticlopidine-associated thrombotic microangiopathy 270
 - transplantation 273–274
 - vascular access 252, 260, 265
 - vasculitis 272
 - vasculitis with hepatitis B-associated polyarteritis nodosa 272
 - voltage-gated potassium channel antibody diseases 269
 - Wilson Disease 273
- API *see* alpha₁-proteinase inhibitor
- aplastic anemia 614–615
- aplastic crisis, sickle cell disease 333–334
- aPTT *see* activated partial thromboplastin time
- Aranesp *see* darbepoetin alfa
- argatroban 415–416
- arginine metabolism, red blood cells 149
- ART *see* antiretroviral therapy
- arterial puncture, blood donation 52–53
- arteriovenous anastomosis, development of method 7–8
- ASP *see* antibody-specific prediction
- ASPEN *see* association of sickle cell priapism, exchange transfusion and neurological events
- aspirin, surgical protocols 460
- ASSC *see* acute splenic sequestration crisis
- Association for the Advancement of Blood and Biotherapies (AABB) 12
- donor screening regulations 39–40, 41–42
 - iron depletion regulations 58–59
 - physical examination requirements 32
 - transfusion services regulations 70–71
- association of sickle cell priapism, exchange transfusion and neurological events (ASPEN) 280
- atherosclerosis, Lewis blood group 89–90
- ATP *see* adenosine 5'-triphosphate
- atrial fibrillation (AF) 460
- atypical chemokine receptor 1 (ACKR1) 112–113
- atypical drug-induced immune thrombocytopenia 412–413
- atypical hemolytic-uremic syndrome (aHUS) 374–375
- Augustine (AUG) blood group system 117
- Aurora platform 253
- Aurora-B kinase (AIM-1 kinase) 159
- autografts 677
- autoimmune diseases, immunoglobulin therapy 241, 245–247
- autoimmune mucocutaneous bullous diseases 247
- autoimmune neutropenia 192–193
- autoimmune thyroiditis 269
- autologous donations 29
- autologous transfusions, nonhemolytic reactions 566
- automated pretransfusion testing 125–127, 128–129
- automated testing systems, infectious diseases 40
- automimmune hemolytic anemias (AIHAs) 346–358
- apheresis 271
 - cold 351–355
 - cold agglutinin disease 351–354
 - drug-induced 356–358
 - mixed 355–356
 - paroxysmal cold hemoglobinuria 354–355
 - pathophysiology 346–348
 - prevalence 346
 - warm 346–351
- Autopheresis-C platform 253
- avatrombopag (Doptelet) 613
- B antigen 81
- B-CAM/LU *see* Basal Cell Adhesion Molecule–Lutheran antigen
- B-transferase (GTB) 81, 83–84
- babesiosis 45, 282, 523–524
- bacterial contamination 533–542
- apheresis 536
 - cryoprecipitate 541
 - culture 536
 - detection 536–538
 - febrile nonhemolytic reactions 555–556
 - first aliquot diversion 535
 - hematopoietic progenitor cells 487
 - international comparisons 541–542
 - large volume delayed sampling 537
 - nucleic acid testing 538
 - pathogen reduction 538–539
 - plasma 541
 - platelets 46, 533–539
 - point of care immunoassays 537–538
 - post-transfusion sepsis prevention 535–540
 - red blood cells 540–541

- secondary culture 536–537
- skin disinfection 535
- bacterial culture 536–537
- barbell protoplatelets 161
- Basal Cell Adhesion Molecule–Lutheran (B-CAM/LU) antigen 111
- BasoEBs *see* basophilic erythroblasts
- basophilic erythroblasts (BasoEBs) 134
- BC method *see* buffy-coat method
- BCEs *see* blood collection establishments
- BCL11A targeted gene editing trials 645–646
- BECS *see* blood establishment computer software
- bedside blood pumps 313
- behavioral theories, blood donors 28
- beta thalassemia 328, 335–336
- BFU-Es *see* burst-forming units-erythroid
- BFU-MK *see* burst-forming units-megakaryocyte
- B3GALNT1 94, 95
- B4GALNT2 97–98
- B4GALNT4 98
- biochemistry
 - clotting 203
 - erythropoiesis 133–141
 - human leukocyte antigens 625–626
 - I blood group 91
 - Lewis blood group 87–88
 - macrocytic anemia 138–140
 - microcytic anemia 140–141
 - P blood group system 93–94
 - pretransfusion testing 118–122
 - red blood cell metabolism 143–150, 144
 - Sd^a antigen 97
 - thalassemia 141
 - therapeutic plasma exchange effects 263–264
- biological agent attacks 16
- biological roles
 - ABO system 86–87
 - human leukocyte antigens 625–626
 - I blood group 92–93
 - Lewis blood group 89–90
 - LW system 107
 - P blood group system 96–97
 - Rh system 105
 - Sd^a antigen 98
- biologically active lipids, transfusion-related acute lung injury 576
- biologics 39
- biophysical niche forces, megakaryopoiesis 164–165
- bioprinting
 - lung tissue engineering 649–650
 - renal tissue 655–656
 - reproductive system tissue 651
- bioreactors, lung tissue engineering 649
- biosynthesis
 - ABO system 81–82
 - hemoglobin 135
 - Lewis blood group 87–88
 - P blood group system 93–94
 - red blood cells 135, 148–149
 - Sd^a antigen 97
- biovigilance 129–130
- bivalirudin 416
- bleeding, plasma transfusion 212–213
- blood administration
 - bedside pumps 313
 - component issue and release 307
 - component modifications 309–310
 - component preparation 309–311
 - cryoprecipitate 210–211, 214–215
 - donor screening 31–32
 - granulocytes 195–198
 - group considerations
 - ABO system 85
 - Diego system 114
 - Duffy protein 113
 - I blood group 92
 - Kell blood group 112
 - Kidd system 113–114
 - Lewis blood group 89
 - MNS blood group 111
 - P blood group 96
 - Rh system 106–107
 - Sd^a antigen 97
 - immunoglobulin G 240–248
 - infusion flow rates 312
 - plasma 209–215
 - adverse reactions 215
 - bleeding treatment 212–213
 - clinical use 212
 - cryoprecipitate 214–215
 - disseminated intravascular coagulation 213
 - prophylactic 213–214
 - pretransfusion considerations 306–307
 - rapid infusion practices 313–314
 - recipient management 129
 - sets and filters 311
 - transfusions 311–313
 - venipuncture 307
 - warming 313
 - see also* administration
- blood avoidance techniques, surgical patients 461–462
- blood banks
 - defective product reporting 72
 - European regulations 75–78
 - FDA regulation 71–72, 78
 - initial development of 9
 - World Health Organization programs 74–75
 - see also* hospital transfusion services
- blood collection 32–36
 - acute adverse reactions 49–55, 256–258
 - administering screening 31–32
 - air embolism 54
 - apheresis 33–34, 53–54, 252–258
 - chronic effects 56–64
 - iron depletion 56–64
 - mitigation 61–62
 - platelet donation 63
 - source plasma 63–64
 - CJD/vCJD risk 31
 - component separation 33
 - donor screening 29–32
 - educational materials 31
 - European regulations 75–78
 - ferritin testing 61–62, 63
 - frequency limitations 61
 - frequency-related adverse reactions 54, 56–64
 - good manufacturing practices 67–68
 - granulocytes 54–55, 487
 - informed consent 31–32
 - iron supplementation 61
 - limiting blood loss 304
 - men who have sex with men 31
 - multiple component collection complications 54
 - patient needs 36
 - phlebotomy-related adverse events 52–53
 - phlebotomy-related nerve injury 53
 - physical examination 32, 34–35
 - postdonation care 32–33
 - presyncopal reactions 50
 - pretransfusion testing 123–124
 - skin disinfection 535
 - source plasma 34–36
 - syncopal reactions 51–52
 - whole blood 32
 - World Health Organization programs 74–75
- blood collection establishments (BCEs)
 - computer software 70
 - device regulatory controls 70
 - educational materials 31
 - European regulations 75–78
 - FDA guidance documents 68–69
 - good manufacturing practices 67–68
 - inspections 69
 - physical examination 32, 34–35
 - postdonation care 32–33
 - reportable deviations 69
 - United States regulations 66–70
 - World Health Organization programs 74–75
 - see also* blood collection
- blood components 131–248
 - adverse reaction reporting 70–73
 - apheresis collection 180, 251, 254–256
 - bacterial contamination 533–542
 - coadministration 311
 - current good manufacturing practices 67–68
 - defective products reporting 69, 72
 - disaster management 18
 - European regulation 75–78

- blood components (*cont'd*)
 - good manufacturing practices 67–68
 - granulocytes
 - collection 194–195
 - donor screening 194–195
 - pediatrics 198, **199**
 - storage 195
 - transfusion 195–199
 - immunoglobulin products 236–248
 - initial usage 9
 - irradiation 155, 186, 221, 309–310
 - issue and release 307
 - leukocyte reduction 33, 155, 186, 309
 - lookback 42
 - manufacturing processes
 - activated prothrombin complex
 - concentrate 227–228
 - albumin 222–224
 - alpha₁-proteinase inhibitor 228
 - antithrombin III 230
 - C1 inhibitor 229–230
 - factor IX 232
 - factor VIII 233–234
 - factor X 227
 - factor XI 228–229
 - factor XIII 227
 - fibrinogen 231
 - immunoglobulins 224–227
 - pathogen reduction 219–221
 - prion safety 222
 - prothrombin complex concentrate
 - 231–232
 - validation of virus reduction/removal
 - 219–220
 - virus filtration 221
 - virus inactivation 220–221
 - virus reduction 219–220
 - von Willebrand factor 232–233
 - neutrophils 188–193
 - clearance 189
 - kinetics 188–190
 - migration 189
 - mobilization 188–189
 - NETosis 189–190
 - neutropenias 190–193
 - neutrophilia 190
 - production 188
 - plasma 200–235
 - adverse reactions 215
 - alternate preparations 209–211
 - bleeding treatment 212–213
 - chromatographic separation
 - 218–219, 222
 - clinical use 212
 - clotting factors 210–211
 - cold ethanol fractionation 217–218
 - cryoprecipitate 210–211, 214–215, 308
 - disseminated intravascular
 - coagulation 213
 - dried 209–210
 - medicinal product manufacturing
 - processes 222–234
 - octanoic acid treatment 221
 - pathogen reduced 210, 219–221
 - pH 221
 - prion safety 222
 - prophylactic 213–214
 - protein purification 216–235
 - solvent and detergent treatment
 - 220–221
 - storage 308
 - transfusion 209–215
 - ultraviolet treatment 221
 - virus filtration 221
 - virus inactivation 220–221
 - virus reduction 219–220
 - warfarin effect 214
 - platelets 158–187
 - ABO system antigens 170–171
 - additive solutions 184–185
 - alloimmunization 171–177
 - alternate sources 181
 - antibody-specific prediction 173–174
 - antigens 168–171
 - apheresis-derived 180
 - buffy-coat method 180
 - centrifugation 186
 - circulatory survival 165
 - containers 183
 - crossmatching 174
 - cryopreservation 186
 - differentiation 158–165
 - HLA-matched transfusions 172–173
 - human leukocyte antigen 168–169
 - human platelet antigens 169–170
 - immunology 168–177
 - irradiation 186
 - kinetics 165–167
 - lesions 183–184
 - leukocyte reduction 186
 - lifespan 165–167
 - lyophilization 186–187
 - megakaryopoiesis regulation
 - 162–165
 - metabolism in storage 181–183
 - modifications 185–186
 - novel storage techniques 186–187
 - pathologies of
 - megakaryopoiesis 161–162
 - pH 182–183
 - plasma removal 186
 - platelet-rich plasma 179
 - plateletpheresis-derivation 180
 - preparation 179–181
 - prevention of alloimmunization
 - 176–177
 - production 158–165
 - refractory evaluation 174
 - respiratory capacity 183
 - sequestration 167
 - storage 181–187, 307
 - storage containers 183
 - storage lesions 183–184
 - temperature 181–182, 186
 - volume reduction 186
 - washing 186
 - preparation 309–311
 - red cells 133–157
 - additive solutions 152–154
 - alternate metabolic substrates
 - 146–147
 - anemia of chronic inflammation 141
 - anticoagulant-nutrient solutions 152
 - biosynthesis 135, 148–149
 - effectiveness 155–156
 - eryptosis 150
 - erythropoiesis 133–142
 - erythropoietic therapies 141–142
 - expiration time 307
 - glucose metabolism 145–148
 - guanine nucleotides 148
 - irradiation 155
 - leukocyte reduction 155
 - macrocytic anemia 138–140
 - membrane metabolism 149–150
 - metabolic regulation 147–148
 - metabolism 143–150
 - microcytic anemia 140–141
 - pathogen reduction 155
 - preservation 150–157
 - quality evaluation 156–157
 - rejuvenation 156
 - separation 151–152
 - storage 154–155, 156, 307
 - temperature and time lapse 154
 - thalassemia 141
 - in vivo recovery 156–157
 - washing 155
 - reportable deviations 69
 - returns 309
 - separation 33
 - apheresis 251
 - testing 37, **38**, 46
 - see also* blood testing
 - transfusion-related deaths reporting 71
 - transport 309
 - United States safety regulations 65–73
 - white cells 188–248
 - granulocytes 193–199
 - neutrophils 188–193
 - World Health Organization programs
 - 74–75
 - see also* administration
 - blood derivatives
 - prerelease testing 46
 - see also* blood testing, donors
 - blood donation
 - acute adverse reactions 49–55, 256–258
 - apheresis 33–34, 252–258
 - autologous 29

- chronic effects 56–64
 - iron depletion 56–64
 - mitigation 61–62
 - plateletpheresis 63
 - source plasma 63–64
- collection 32–36
- component separation 33
- demographics 27
- development of 9
- direct antiglobulin testing 39
- directed 29
- disasters 28–29
- exception medical needs 29
- ferritin testing 61–62, 63
- frequency limitations 61
- granulocytes 487
- iron supplementation 61
- operational chain 11
- patient needs 36
- physical examination 32, 34–35
- postdonation care 32–33
- recipient-specific 29
- recruitment 27–29
- screening 29–32, 37–48
- source plasma 34–36
- testing 37–48
 - see also* blood testing, donors
 - whole blood 32
 - see also* blood collection
- blood establishment computer software (BECS) 70
- blood groups 329–330
 - ABCC1 system 117
 - ABO system 81–87, 330
 - antibodies 120–122
 - antibody classes 121
 - AUG system 117
 - carbohydrate 81–99
 - Cartwright system 115
 - Chido/Rogers system 115
 - Colton system 114–115
 - compatibility testing 8
 - crossmatching 128–129
 - CTL2 system 117
 - Diego system 114
 - discovery 7
 - DNA-based typing 127–128
 - Dombrock system 115–116
 - Duffy system 112–113, 329
 - extended antigen typing 47
 - Gerbich system 115, 329
 - GIL system 114–115
 - I system 90–93
 - Indian system 115
 - inheritance discovery 8
 - JR system 116
 - Kell system 111–112
 - Kidd system 113–114
 - Knops system 115, 330
 - LAN system 116
 - Lewis system 87–90, 330
 - Lutheran system 111
 - LW system 107
 - MAM system 117
 - MNS system 109–111, 330
 - OK system 116
 - P system 93–97
 - PEL system 116–117
 - pretransfusion testing 123–130
 - RAPH system 116
 - Rh system 100–107
 - Scianna system 114
 - Sd^a 97–99
 - unit selection 128
 - Vel system 117
 - Xg system 114
- blood loss, pregnancy 373–375
- blood recovery systems 299–301
- Blood Regulators Network, WHO (BRN) 75
- blood safety
 - adverse reaction reporting 70–73
 - biovigilance 129–130
 - blood collection establishment
 - regulation, US 66–70
 - defective products reporting 69, 72
 - donor screening 29–32
 - European regulations 75–78
 - hospital transfusion services regulation, US 70–73
 - initial concerns 10–11
 - reportable deviations 69
 - testing 37–48
 - see also* blood testing
 - transfusion-related deaths reporting 71
 - United States regulations 37, 38, 39–40, 41–42, 65–73
 - US accreditation 73
 - World Health Organization
 - requirements 39, 74–75
- blood services
 - current system organization 11–13
 - operational chain 11
 - United States organizations 12
 - worldwide organization 12–13
 - see also* blood donation
- blood testing
 - compatibility testing 122–130
 - donors 37–48, 40
 - ABO antibody titers 38–39
 - ABO typing 37–39, 38
 - automated systems 40
 - babesiosis 45
 - blood derivatives 46
 - Chagas' disease 46
 - components 37, 38
 - cytomegalovirus 46
 - direct antiglobulin testing 39
 - extended blood group antigen typing 47
 - false positives 39
 - hemoglobin S 47
 - hepatitis A 47
 - hepatitis B 43–44
 - hepatitis C 44
 - HIV 43
 - human leukocyte antigen 47
 - human T-cell lymphotropic virus 44
 - IgA deficiency 47
 - infectious diseases 37, 39–47
 - lookback 42
 - management of donors 41–42, 41
 - Parvovirus B19 47
 - platelet antigen typing 47
 - platelets 46
 - pooling 39, 43
 - product management 42
 - RBC antigens 38
 - recipient notification 42
 - reentry 41, 42–43
 - regulations 39–40, 41–42
 - resource-limited settings 40
 - Rh groups 37–38
 - Rh system 37–38
 - Rh typing 37–38
 - sequence 40
 - source plasma donors 38–41
 - syphilis 45–46
 - transfusion-transmitted infections 37, 39–47
 - United States regulations 37, 38, 39–40, 41–42
 - West Nile virus 45
 - World Health Organization
 - requirements 39
 - Zika virus 45
 - Blundell, J. 5–6
 - Bombay phenotype 83
 - para*-Bombay phenotype 83
 - bone allografts 673–674
 - bone marrow
 - collagen fibrosis 614
 - microenvironment 617–619
 - paroxysmal nocturnal
 - hemoglobinuria 363
 - reticulin fibrosis 614
 - bone tissue engineering 656
 - bradykinin (BK) 265
 - Braxton-Hicks, J. 6–7
 - breast cancer, I blood group 93
 - breast milk, hemolytic disease of the fetus
 - and newborn 371
 - BRN *see* Blood Regulators Network, WHO
 - bronchoscopy
 - plasma administration 468
 - platelet administration 469
 - bruises, blood donation 52
 - buffy-coat (BC) method 180

- burn patients 471, 478–481
 - coagulation factor replacement 480
 - cryoprecipitate 480
 - freeze-dried plasma 480
 - initial resuscitation 478
 - prothrombin complex concentrates 480
 - recombinant activated factor VII 480
 - skin allografts 675
 - tranexamic acid 479–480
 - transfusion therapy 478–479
 - whole blood 480
- burst-forming units-erythroid (BFU-Es) 134, 135–136
- burst-forming units-megakaryocyte (BFU-MK) 159
- bystander hemolysis 547
- C/c antigens, Rh system 102–103
- C/EBP α *see* CCAAT/enhancer binding protein α
- C1 inhibitor 201, 229–230
- CAD *see* cold agglutinin disease
- calcium supplementation, apheresis 54
- calculated panel-reactive antibody (CPRA) tests 630–631
- California maternal quality care collaboration (CMQCC) 376
- Campylobacter jejuni* 86–87
- Canadian Blood Services (CBS), physical examination requirements 32
- cancer
 - ABO system 86
 - adverse reactions 487–488
 - chimeric antigen receptor T-cell therapy 488
 - erythroid growth factors 605
 - granulocyte transfusions 486–487
 - I blood group 93
 - Lewis blood group 89–90
 - neutropenia 192
 - P blood group system 95, 96
 - platelet transfusions 484–486
 - red blood cell administration 322, 482–484
 - Sd^a antigen 98
 - T-cell immunotherapies 633, 636–637
 - thrombocytopenia 394
 - thrombopoietic growth factors 614
 - transfusion support 482–488
 - see also specific forms of cancer. . .*
- CAP *see* College of American Pathologists
- caprylate *see* octanoic acid
- CAPS *see* catastrophic antiphospholipid syndrome
- CAR *see* chimeric antigen receptor
- carbohydrate blood groups 81–99
 - ABO system 81–87
 - I system 90–93
 - Lewis system 87–90
 - P system 93–97
 - Sd^a antigen 97–99
- carboxylic acids, red blood cell synthesis 148
- cardiac allografts 676–677
 - rejection, extracorporeal photopheresis 287–288
- cardiac surgery
 - platelet administration 470
 - red blood cell administration 319–321
- cardiac tissue engineering 657
- Carrel, A. 7
- cartilage, allografts 674
- cartilage tissue engineering 657–658
- Cartwright blood group system 115
- CASI *see* computer-assisted self-interview
- catastrophic antiphospholipid syndrome (CAPS), apheresis 271
- CBER *see* Center for Biologics Evaluation and Research
- CBS *see* Canadian Blood Services
- CCAAT/enhancer binding protein α (C/EBP α) 91–92
- CD17 *see* transferrin receptor
- CD40 ligand, transfusion-related acute lung injury 576
- CD105 *see* endoglin
- CDER *see* Center for Drug Evaluation and Research
- CD–P–TS *see* European Committee on Blood Transfusion
- CDRH *see* Center for Devices and Radiologic Health
- CDSS *see* clinical decision support systems
- cell salvage 299–301
 - devices 312
 - obstetrics 377
- cell-based immunotherapies, storage 308
- Center for Biologics Evaluation and Research (CBER) 68
- Center for Devices and Radiologic Health (CDRH) 68
- Center for Drug Evaluation and Research (CDER) 67, 68
- central venous catheters (CVCs)
 - insertion 466–467, 469
 - therapeutic plasma exchange 260
- centrifugation, platelets 186
- ceramide lipid tails 93
- CFR *see* US Code of Federal Regulations
- CFU-Es *see*
 - colony-forming units-erythroid
- CFU-MK *see* colony-forming units-megakaryocyte
- cGMP *see* current good manufacturing practices
- Chagas disease 46, 524–525
- Chediak–Higashi syndrome 191
- chelation
 - compliance 594–595
 - initiation 594
 - intensification 595
- iron overload 592–596
 - monitoring 595–596
- chemical agent attacks 16
- chemistry, ABO system 81–82
- chemotherapeutics, cold agglutinin disease 353
- chemotherapy-induced neutropenia 609–610
- chemotherapy-induced thrombocytopenia (CIT) 615
- Chido/Rogers blood group system 115
- chikungunya virus (CHIKV) 518
- CHIKV *see* chikungunya virus
- children 381–391
 - anemia 383
 - coagulation system development 388–389
 - cryoprecipitate transfusions 390–391
 - granulocyte transfusions 198, **199**
 - I blood group 90–93
 - immune thrombocytopenic purpura 410–411
 - paroxysmal nocturnal hemoglobinuria 363
 - plasma transfusions 388–390
 - platelet transfusions 385–388
 - red blood cell administration 322
 - red blood cell transfusions 383–385
 - therapeutic plasma exchange 266
 - TRALI 573
 - see also* infants; neonates
- chimeric antigen receptor (CAR) T-cell therapy 634, 635–637
 - adverse reactions 488
- chlorpromazine 192
- CHMP *see* Committee for Medicinal products for human Use
- cholera, ABO system 86–87
- choline transporter-like protein-2 (CTL2) system 117
- chromatographic separation
 - albumin 222–223
 - plasma 218–219, 222
- chromium-51 labeling 156–157
- chronic anemia
 - maternal 375
 - red blood cell administration 324
- chronic autoimmune diseases, immunoglobulin therapy 246–247
- chronic effects
 - donation-related 56–64
 - iron depletion 56–64
 - mitigation 61–62
 - neurocognitive 60
 - pica 60–61
 - platelet donation 63
 - pregnancy-related 60
 - restless legs syndrome 60
 - source plasma 63–64
 - vulnerable populations 61

- chronic inflammation
 - anemia 141
 - immunoglobulin therapy 246–247
- chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
 - apheresis 267
 - immunoglobulin therapy 246
- chronic liver disease, coagulation factor concentrates 451
- chronic renal failure, erythroid growth factors 605
- chronic transfusion therapy (CTT)
 - sickle cell disease 280–281, 331–335, **332**
 - thalassemia 335–337
- CIDP *see* chronic inflammatory demyelinating polyradiculoneuropathy
- circular preplatelets 160–161
- circulation, discovery of 3
- circulatory overload 563–564
- circulatory survival, platelets 165
- CIT *see* chemotherapy-induced thrombocytopenia
- citrate anticoagulants 8–9, 53–54, 251, 257, 266, 561–562
- citrate phosphate dextrose adenine (CPDA-1) solutions 151, 152
- citrate phosphate dextrose (CPD) solutions 151, 152
- citrate phosphate double dextrose (CP2D) solutions 152
- citrate reactions 53–54
- citrate toxicity 257, 266, 561–562
- CJD *see* Creutzfeldt–Jakob disease
- Clair Y g, purification 226
- classifications, von Willebrand disease 434–436
- clearance, neutrophils 189
- CLIA *see* Clinical Laboratory Improvement Act
- clinical decision support systems (CDSS) 295–297
- clinical features
 - cold agglutinin disease 352–353
 - combined factor V and factor VIII deficiency 438
 - drug-induced immune hemolytic anemia 357
 - factor V deficiency 437–438
 - factor VII deficiency 438
 - factor X deficiency 439
 - factor XI deficiency 439–440
 - factor XIII deficiency 440
 - hemolytic transfusion reactions 547–550
 - hemophilia 425
 - immune thrombocytopenic purpura 406–407
 - iron overload 590
 - paroxysmal cold hemoglobinuria 354–355
 - paroxysmal nocturnal hemoglobinuria 359–360
 - prothrombin deficiency 437
 - transfusion-related acute lung injury 569–570
 - von Willebrand disease 434
 - warm autoimmune hemolytic anemia 348–349
- Clinical Laboratory Improvement Act (CLIA) 70, 71
- clinical outcomes
 - anemia 317–319
 - cold agglutinin disease 354
 - paroxysmal cold hemoglobinuria 355
 - paroxysmal nocturnal hemoglobinuria 363
 - red blood cell administration 318–322
 - transfusion-related acute lung injury 573
 - warm autoimmune hemolytic anemia 351
- clonal selection 120
- clonality 120
- clopidogrel, surgical protocols 460
- clotting factors 204
 - in plasma 201–202, 203
 - storage 308
- clozapine 192
- Clustered Regularly-Interspaced Short Palindromic Repeats (CRISPR) 644
- CM-TMA *see* complement-mediated thrombotic microangiopathy
- CMQCC *see* California maternal quality care collaboration
- CMV *see* cytomegalovirus
- coadministration
 - fluids and components 311
 - medications 311–312
- coagulation
 - ABO system 86
 - activation and regulation 203, 204
 - screening tests 204–208, 457–458
- coagulation factor inhibitors, in plasma 201–202
- coagulation factors 424–442
 - acquired bleeding disorders 443–452
 - afibrinogenemia 441
 - burn patients 480
 - combined factor V and factor VIII deficiency 438
 - dysfibrinogenemia 441–442
 - factor V deficiency 438
 - factor VII deficiency 438–439
 - factor X deficiency 439
 - factor XI deficiency 439–440
 - factor XIII deficiency 440–441
 - fibrinogen disorders 441
 - hemophilia 426–432
 - hypodysfibrinogenemia 441–442
 - hypofibrinogenemia 441
 - inherited bleeding disorders 424–442
 - obstetrics 377
 - in plasma 201–202, 203, 204–205
 - prothrombin deficiency 437
 - trauma patients 480
 - von Willebrand disease 436
 - see also* factor-*n*. . .
- coagulopathies, trauma patients 474–475
- cobalamin deficiency, macrocytic anemia 138–140
- CoE *see* Council of Europe
- Coga, A. 4
- Cohn, E.J. 9
- Cohn process
 - albumin 222–223
 - alpha₁-proteinase inhibitor 228
 - immunoglobulins 224–226
- cold agglutinin disease (CAD)
 - clinical features 352–353
 - pathophysiology 351–352
 - prognosis 354
 - treatment 353–354
- cold autoimmune hemolytic anemia 351–355
- cold ethanol fractionation 9, 217–218
 - albumin 222–224
 - immunoglobulins 224–226
- collagen fibrosis 614
- College of American Pathologists (CAP) 17
 - transfusion services regulations 70, 73
- colon cancer
 - I blood group 93
 - Sd^a antigen 98
- colony-forming units-erythroid (CFU-Es) 134–135
- colony-forming units-megakaryocyte (CFU-MK) 159
- Colton blood group system 114–115
- combined factor V and factor VIII deficiency 438
- Committee for Medicinal products for human Use (CHMP) 76–77
- communication, donor screening results 41–42
- compatibility testing 122–130
 - donor testing 122–123
 - granulocyte collection 194–195
 - Ottenberg 8
 - patient testing 123–130
- complement, hemolytic transfusion reactions 545–547
- complement scavenging, immunoglobulins 244
- complement-mediated thrombotic microangiopathy (CM-TMA), apheresis 270
- compliance, chelation 594–595

- complications
 - apheresis 256–258
 - hemolytic transfusion reactions 550
 - massive transfusion protocols 561–564
 - rapid infusion practices 561–564
 - red blood cell transfusion 342–345
 - therapeutic plasma exchange 264–266
 - see also* adverse reactions; adverse sequelae
 - component therapy
 - disaster management 18
 - initial development of 9
 - irradiation 309–310
 - leukoreduction 309
 - see also* administration; blood components
 - composition of plasma 200–208
 - albumin 200
 - alpha-1 antitrypsin 201
 - C1 inhibitor 201
 - clotting factors 201–202, 203
 - coagulation factor inhibitors 201, 203
 - factors influencing 202–203
 - fibrinolysis 203–208
 - immunoglobulins 201
 - von Willebrand factor 201–202
 - computer-assisted self-interview (CASI) 32
 - computerized physician order entry (CPOE) systems 295–296
 - confirmatory testing, HIV 43
 - congenital neutropenias 191–192
 - connective tissue allografts 674–675
 - consent, recipients 129
 - containment, health emergencies 22
 - contaminant levels, albumin 224
 - continuity of operations plans (COOP) 17, 17
 - continuous renal replacement therapy (CRRT) 263
 - contraindications
 - cell salvage 301
 - heparin-induced thrombocytopenia 416–417
 - sickle cell disease 335
 - convalescent plasma 23, 212
 - conventional-dose therapy, subcutaneous therapy 240
 - COOP *see* continuity of operations plans
 - cord blood 621
 - corticosteroids
 - immune thrombocytopenic purpura 407
 - warm autoimmune hemolytic anemia 350
 - Council of Europe (CoE) 76–77
 - COVID-19 14, 16, 18–23
 - ABO type 87
 - cell-based therapies 650
 - convalescent plasma 23
 - hematopoietic stem cells 622–623
 - vaccine-induced immune thrombotic thrombocytopenia 417
 - COX2 *see* cyclooxygenase 2
 - CP2D *see* citrate phosphate double dextrose
 - CPD *see* citrate phosphate dextrose
 - CPDA-1 *see* citrate phosphate dextrose adenine
 - CPOE *see* computerized physician order entry systems
 - CPRA *see* calculated panel-reactive antibody tests
 - Creutzfeldt–Jakob disease (CJD) 11, 31, 529–531
 - crisis standards of care 16–17
 - CRISPR *see* Clustered Regularly-Interspaced Short Palindromic Repeats
 - critical care
 - red blood cell administration 319
 - transfusion-related acute lung injury 577
 - cross-reactive groups (CREGs), human leukocyte antigens 172–173
 - crossmatching 128–129
 - platelets 174, 400, 484
 - CRRT *see* continuous renal replacement therapy
 - CRS *see* cytokine release syndrome
 - cryoglobulinemia, apheresis 271–272
 - cryoprecipitate
 - administration 210–211
 - burn patients 480
 - children 390–391
 - hemophilia 426–427
 - therapeutic plasma exchange 262–263
 - trauma patients 480
 - bacterial contamination 541
 - blood collection 32
 - clinical use 214–215
 - separation 33
 - storage 308
- cryopreservation, hematopoietic stem cells 620–621
- CTCL *see* cutaneous T-cell lymphoma
- CTL2 (choline transporter-like protein-2) system 117
- CTT *see* chronic transfusion therapy
- current good manufacturing practices (cGMP) 67–68
- cutaneous T-cell lymphoma (CTCL) 287
- CVCs *see* central venous catheters
- cyclic neutropenia 192
- cyclooxygenase 2 (COX2) inhibitors 432
- cysteine metabolism, red blood cells 148
- cytapheresis *see* therapeutic plasma exchange
- cytokine release syndrome (CRS) 488
- cytokines
 - megakaryopoiesis regulation 162–164
 - storage-generated 555
- cytomegalovirus (CMV) 519
 - neutropenia 192
 - testing 46
- cytotoxic agents, cold agglutinin disease 353
- D antigen, Rh system 101
- D antigen testing 37–38
- damage-associated pattern molecules (DAMPs) 474–475
- damage-control resuscitation 475–478
- DAMPs *see* damage-associated pattern molecules
- danazol 410
- darbepoetin alfa (Aranesp) 603–604
- DAT *see* direct antiglobulin testing
- DBCD *see* Division of Blood Components and Devices
- DC *see* dendritic cell
- DDAVP *see* desmopressin
- decision-making, red blood cell transfusions 323
- defective products, reporting 69, 72
- deferasirox (ICL670Q / Exjade / DFX) 593–594
- deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one / DFP / L1) 593
- deferoxamine B mesylate (DFO / Desferal) 592–593
- deglycerolizing, red blood cells 156
- dehydrated hereditary stomatocytosis (DHSt) 339
- delayed acute adverse reactions, blood donation 50
- delayed hemolytic transfusion reactions (DHTRs) 343–344, 543–552
 - see also* hemolytic transfusion reactions
- DEM *see* Donor Educational Materials
- demarcation membrane system (DMS) 160
- demographics, blood donors 27
- denaparoid sodium 416
- dendritic cell (DC) immunotherapy 638
- dengue virus 517–518
- Denis, J-B. 4–5
- Department of Homeland Security (DHS) 15
- desensitization, therapeutic plasma exchange 274
- Desferal *see* deferoxamine B mesylate
- desmopressin (DDAVP) 203, 303–304, 432, 436, 448–449
 - adverse reactions 448–449
 - dosing 448
 - indications 448
 - manufacturing 448
 - oncology patients 486
 - storage 448
- DETTD *see* Division of Emerging and Transfusion Transmitted Diseases

- devices
 administration sets and filters 311
 donor apheresis 253–254
 regulatory controls 70
 therapeutic plasma exchange 259–260
 DFO *see* deferoxamine B mesylate
 DFP *see* deferiprone
 DFX *see* deferasirox
 DHQ *see* Donor History Questionnaire
 DHS *see* Department of Homeland Security
 DHSt *see* dehydrated hereditary stomatocytosis
 DHTRs *see* delayed hemolytic transfusion reactions
 diagnosis
 allergic responses 558–559
 anaphylaxis 560
 babesiosis 524
 Chagas disease 525
 combined factor V and factor VIII deficiency 438
 cytomegalovirus 519
 dengue virus 517
 dysfibrinogenemia 441
 factor V deficiency 438
 factor VII deficiency 438
 factor X deficiency 439
 factor XI deficiency 440
 factor XIII deficiency 440
 febrile nonhemolytic reactions 556
 hemolytic transfusion reactions 547–550
 hepatitis A 507–508
 hepatitis B 510–511
 hepatitis C 511
 herpesviruses 519
 hypodysfibrinogenemia 441
 prothrombin deficiency 437
 transfusion-associated graft-versus-host disease 584–585
 transfusion-related acute lung injury 571–572
 transfusion-related circulatory overload 580
 von Willebrand disease 434–436
 West Nile Virus 518
 diagnostic testing, health emergencies 22
 dialysis, thrombocytopenia 394
 DIC *see* disseminated intravascular coagulation
 Diego blood group 81, 110, 114
 differentiation
 erythroid progenitor cells 133–134, 137–138
 hematopoietic stem cells 133
 megakaryocytes 159–165
 platelets 158–165
 DIIHA *see* drug-induced immune hemolytic anemia
 dilated cardiomyopathy (DCM), apheresis 275–276
 dimethyl sulfoxide (DMSO)
 toxicity 565–566
 1,2-dimethyl-3-hydroxypyridin-4-one *see* deferiprone
 2,3-diphosphoglycerate (2,3-DPG) 143, 145–146, 147–148, 151, 153, 155–156
 direct antiglobulin test (DAT) 39, 122
 paroxysmal cold hemoglobinuria 354–355
 warm autoimmune hemolytic anemia 347–349
 direct oral anticoagulants (DOACs), surgical protocols 460
 direct transfusion, development of method 7–8
 directed donations 29
 disaster management 14–20
 blood components 18
 continuity of operations plans 17, 17
 COVID-19 14, 16, 18–23
 extraordinary donation volumes 28–29
 local plan development resources 15
 mitigation 14
 national authorities 15–16, 18
 operations organization 15–16
 preparedness 14–15, 16–17
 records management 18
 recovery 15
 regulatory considerations 17–18
 responses 15
 see also health emergencies
 disialogalactosylgloboside (DSGG) 94
 disseminated intravascular coagulation (DIC)
 coagulation factor concentrates 450–451
 plasma transfusion 213
 pregnancy 375
 dithiothreitol (DTT) 107
 DITP *see* drug-induced immune thrombocytopenic purpura
 Division of Blood Components and Devices (DBCD) 68
 Division of Emerging and Transfusion Transmitted Diseases (DETTD) 68
 DMS *see* demarcation membrane system
 DMSO *see* dimethyl sulfoxide
 DNA-based blood group typing 127–128, 129
 DOACs *see* direct oral anticoagulants
 Dombrock blood group system 115–116
 donation tracking, allografts 678–679
 Donor Educational Materials (DEM) 31–32
 Donor History Questionnaire (DHQ) 30–31
 donor–recipient testing 128–129
 donors
 acute adverse reactions 49–55
 apheresis 53–55, 256–258
 citrate reactions 53–54, 257
 frequency-related 54
 granulocyte collection 54–55
 multiple component collection 54
 phlebotomy-related 52–53
 presyncopal 50, 257
 risk factors 51, 53
 syncopal 51–52
 apheresis 252–258
 complications 256–258
 devices 253–254
 procedure requirements 254–256
 product requirements 254–256
 autologous 29
 blood collection 32–36, 252–258
 chronic effects 56–64
 blood collection 56–62
 mitigation 61–62
 plateletpheresis 63
 source plasma 63–64
 demographics 27
 directed 29
 exceptional medical needs 29
 frequency limitations 61
 granulocyte collection 194–195, 487
 iron supplementation 61
 management 41–42
 transfusion-related acute lung injury 577–578
 physical examination 32, 34–35
 postdonation care 32–33
 pregnancy 33
 re-entry 42–43
 recipient-specific 29
 recruitment 27–29
 behavioral theories 28
 disasters 28–29
 recipient-specific 29
 retention 28
 repeat 28
 retention 28
 screening 29–32, 37–48
 ABO antibody titers 38–39
 ABO system 37–39, 38
 administration 31–32
 automated systems 40
 bacterial infections 535
 CJD/vCJD risk 31
 communicating results 41–42
 direct antiglobulin testing 39
 Donor History Questionnaire 30–31
 educational materials 31
 ferritin levels 61–62, 63
 granulocyte collection 194–195
 infectious diseases 37, 39–47
 informed consent 31–32
 lookback on discovery of disease 42
 men who have sex with men 31

- donors (*cont'd*)
 RBC antibody detection 38
 re-entry 42–43
 Rh system 37–38
 source plasma 34–35, 38–41
 transfusion-related acute lung injury 577
 vital sign measurement 32
see also blood testing, donors;
 prerelease testing
 source plasma 34–36, 38–41
- Doptelet *see* avatrombopag
- dosing
 activated prothrombin complex concentrate 445
 andexanet alfa 450
 antifibrinolytics 448
 desmopressin 448
 factor VIII 427
 idarucizumab 450
 immunoglobulin therapy 244–247
 platelet transfusions 397
 protamine 449
 prothrombin complex concentrates 444
 recombinant activated factor VII 445
 red blood cell administration 324
 vitamin K 446–447
- 2,3-DPG *see* 2,3-diphosphoglycerate
- 2,3-DPG shunt (Rapoport–Luebering shunt) 145–146, 147
- dried plasma 209–210
- drug interactions, immunoglobulin therapy 241
- drug-induced autoimmune thrombocytopenia 413
- drug-induced immune hemolytic anemia (DIIHA) 356–358
- drug-induced immune thrombocytopenias 411–417, **412**
- drug-induced immune thrombocytopenic purpura (DITP) 411–412
- drug-induced thrombotic microangiopathy 413
- dry heat, virus inactivation 220
- DSGG *see* disialogalactosylgloboside
- DTT *see* dithiothreitol
- du Mauroy, A. 5
- Duffy blood group system 112–113, 329
- dura mater allografts 675
- dysfibrinogenemia 441–442
- dyspnea 580
- E/e antigens, Rh system 102–103
- ebola virus 520–521
- EBV *see* Epstein–Barr virus
- ECBS *see* Expert Committee on Biological Standardization
- ECMO *see* extracorporeal membrane oxygenation
- ECP *see* extracorporeal photopheresis
- eculizumab
 cold agglutinin disease 353
 paroxysmal nocturnal hemoglobinuria 361–362, 363
- EDQM *see* European Directorate for the Quality of Medicines
- education, physicians 295–297
- educational materials, donors 31
- effectiveness, red blood cells 155–156
- efficacy of pathogen reduction 493–495
- ELANE gene mutations 191
- electrolyte disorders 562–563
- eltrombopag (Promacta / Revolade) 613
- EMA *see* European Medicines Agency
- EMAs *see* emergency management agencies
- agencies
 Embden–Meyerhof–Parnas pathway (EMP) 145
- embryonic development
 I blood group 93
 P blood group system 96
- emergency management agencies (EMAs) 16–17
- emergency operations, organization 15–16
- emergency release 129
- emergency treatment, immune thrombocytopenic purpura 410
- EMP *see* Embden–Meyerhof–Parnas pathway
- endoglin (CD105) 134
- engineered T cell receptor expressing T cell therapy 634–637
- ENT1 *see* equilibrative nucleoside transporter 1
- enteric infections
 ABO system 86–87
 Lewis blood group 89–90
 P blood group 97
 Sd^a antigen 99
- enzymopathies, red blood cells 328–329, 337–338
- epidemiological surveillance, health emergencies 22
- epidemiology
 alloimmune thrombocytopenia 418–419
 cold autoimmune hemolytic anemia 351
 drug-induced immune hemolytic anemia 356
 paroxysmal nocturnal hemoglobinuria 358
 paroxysmal cold hemoglobinuria 354
 physical injury 472–473
 transfusion-related acute lung injury 572–573
 warm autoimmune hemolytic anemia 346
see also prevalence
- epidural anesthesia
 plasma administration 468
 platelet administration 470
- epitopes
 ABO system 81–82
 human leukocyte antigens 631
 Kell blood group 112
 P blood group system 93–94
- EPO *see* erythropoietin
- epoetin alfa (Epogen / Procrit) 603
- epoetin alfa-epbx (Retacrit) 603
- Epogen *see* epoetin alfa
- Epstein–Barr virus (EBV) 192, 519
- equilibrative nucleoside transporter 1 (ENT1) 117
- error reporting
 defective products 69, 72
 transfusion services 71–72
- eryptosis 150
- erythrocytapheresis 282–285
 hereditary hemochromatosis 285
 polycythemia vera 283
 protocol 341
 secondary erythrocytosis 284
- erythroid growth factors 603–606
 adverse effects 604–605
 indications 605
- erythroid maturation agents 596
- erythroid progenitor cells 133–134, 137–138
- erythropoiesis 133–142
 anemia of chronic inflammation 141
 extracellular requirements 135–136
 hemoglobin synthesis 135
 intracellular requirements 135
 macrocytic anemia 138–140
 microcytic anemia 140–141
 nutritional requirements 138–142
 stages 133–134
 thalassemia 141
 therapies 141–142
- erythropoietin (EPO) 136–138
- erythropoietin-stimulating agents (ESAs) 484
- ESAs *see* erythropoietin-stimulating agents
- Escherichia coli*, P blood group system 97
- essential thrombocythemia (ET)
 apheresis 285–286
 platelet lifespan 165–166
- ET *see* essential thrombocythemia
- EUHASS *see* European Hemophilia Safety Surveillance
- European Committee on Blood Transfusion (CD–P–TS) 77
- European Directorate for the Quality of Medicines (EDQM) 76–77
- European Hemophilia Safety Surveillance (EUHASS) 78
- European Medicines Agency (EMA) 76–77

- European Pharmacopeia (PhEur) 77
- European regulations 75–78
- albumin 223–224
 - alpha₂-proteinase inhibitor 228
 - antithrombin III 230
 - Council of Europe 76–77
 - European Union 76
 - factor IX 232
 - factor XI 228–229
 - fibrinogen preparations 231
 - immunoglobulins 226–227
 - medicines safety monitoring 77
 - plasma derivatives and recombinant products 77
 - prothrombin complex concentrate 232
 - von Willebrand factor 233
- evidence-based guidelines, patient blood management 294–295
- exceptional medical needs, blood donations 29
- exchange volumes, therapeutic plasma exchange 260–261
- Exjade *see* deferasirox
- Expert Committee on Biological Standardization (ECBS) 75
- expiration time, red blood cells 307
- expression
- ABO system 81–82, 84, 85
 - I blood group 90–91, 92–93
 - Lewis blood group 88–89
 - LW system 107
 - P blood group system 93–94, 96
 - Rh system 101–104
 - Sd^a antigen 97–98
- extended blood group antigen typing 47
- extended phenotype testing 127–128, 129
- extracellular requirements, erythroid differentiation 135–136
- extracorporeal membrane oxygenation (ECMO) 263
- extracorporeal photopheresis (ECP) 287–289
- allograft rejection 287–288
 - cutaneous T-cell lymphoma 287
 - graft-versus-host disease 288–289
- extraembryonic tissue preservation/transplantation 677
- extrinsic pathway 204
- F-actin, megakaryocytes 160, 161
- factor II (prothrombin) 201, 437
- factor IX 201, 204–205
- hemophilia 431–432
 - purification 232
- factor V 201
- deficiency 437–438
- factor VII deficiency 438–439
- factor VIII 201, 428–430
- cryoprecipitate transfusion 210–211
 - hemophilia 427
 - purification 233–234
 - von Willebrand disease 436–437
- factor VIII inhibitor bypassing activity (FEIBA) 227–228
- factor X 201, 204–205
- deficiency 439
 - purification 227
- factor XI 201, 204–205
- deficiency 439–440
 - purification 228–229
- factor XII 201, 204–205
- factor XIII
- cryoprecipitate transfusion 210–211
 - deficiency 440–441
 - purification 227
- factor-*n*, *see also* recombinant. . .
- false positives, infectious disease screening 39
- familial hypercholesteremia (FH), apheresis 276
- fascia lata allografts 675
- FC *see* fibrinogen concentrates
- FCR *see* fraction of the preprocedure cells remaining
- FDA *see* United States Food and Drug Administration
- febrile nonhemolytic transfusion reactions (FNHTRs) 553–558
- alloimmunization 555
 - bacterial contamination 555–556
 - diagnosis 556
 - etiology 554
 - leukocyte reduction 557–558
 - prevention 557–558
 - storage-generated cytokines 555
 - treatment 556–557
- Federal Emergency Management Agency (FEMA) 15
- FEIBA *see* factor VIII inhibitor bypassing activity
- Felty syndrome 192
- FEMA *see* Federal Emergency Management Agency
- Fenwal Amicus instrument 253
- ferritin
- depletion
 - absent iron stores 57
 - adverse outcomes 59–61
 - blood donors 56–62
 - iron-deficient erythropoiesis 57
 - mitigation 61–62
 - monitoring 61–62, 63
 - neurocognitive effects 60
 - pica 60–61
 - pregnancy-related outcomes 60
 - restless legs syndrome 60
 - source plasma donation 63–64
 - vulnerable populations 61
- monitoring 61–62, 63
- fetal development
- I blood group 93
 - P blood group system 96
- fetal hemoglobin (HbF) inducers 596
- fetal transfusions 379–380, 420–421
- fetal typing 105, 379
- fetal/neonatal alloimmune thrombocytopenia (FNAIT) 379–380
- FFP *see* fresh frozen plasma
- FH *see* familial hypercholesteremia
- fibrin clot formation 203
- fibrin stabilization 203
- fibrinogen 201
- purification 231
 - viral-inactivated purified concentrate 211
- fibrinogen concentrates (FC) 211, 304
- obstetrics 377
 - oncology patients 486
- fibrinogen disorders 441
- fibrinolysis 203–208
- screening tests 204–208
- Fibrogammin, purification 227
- FII *see* prothrombin
- Filamin A 161
- filgrastim (Neupogen) 607
- filgrastim-aafi (Nivestym) 607–608
- filgrastim-sndz (Zarxio) 607–608
- filters 311
- filtration, viruses 221
- first aliquot diversion 535
- flaviviruses 517–518
- Flebogaam DIF, purification 224–225
- FLI1-related thrombocytopenia 161
- Flosdorf, E.W. 9
- flow cytometry, paroxysmal nocturnal hemoglobinuria 360
- fluids, coadministration 311
- FNAIT *see* fetal/neonatal alloimmune thrombocytopenia
- FNHTRs *see* febrile nonhemolytic transfusion reactions
- focal segmental glomerulosclerosis (FSGS), apheresis 272–273
- folate deficiencies, macrocytic anemia 138–140
- fondaparinux 416
- Food, Drug, and Cosmetic Act (FDCA) 66
- device regulatory controls 70
 - hospital transfusion services 71
- Forssman phenotype 95–96
- Forssman synthase (*GBGT1*) 96
- fostamatinib 409
- fraction of the preprocedure cells remaining (FCR) 278–279
- frequency-related adverse reactions, blood collection 54

- fresh frozen plasma (FFP)
 adverse reactions 215
 bleeding treatment 212–213
 burn patients 480
 clinical uses 212
 combined factor V and factor VIII deficiency 438
 disseminated intravascular coagulation 213
 factor V deficiency 438
 hemophilia 426–427
 pathogen reduction 495–496
 preparation 33
 prophylactic use 213–214
 prothrombin deficiency 437
 storage 308
 therapeutic plasma exchange 214, 262–263
 trauma patients 480
 warfarin effect reversal 214
 frozen bone 673
 frozen storage
 plasma composition effects 203
 platelets 186
 red blood cells 156
 FSGS *see* focal segmental glomerulosclerosis
 Fulphilia *see* pegfilgratim-jmdb
 FUT1 83, 84–85
 FUT2 81, 82, 89
 FUT3 88–89
 FV/FVIII *see* combined factor V and factor VIII deficiency

 G proteins, red blood cells 148
 G6PD *see* glucose-6-phosphate dehydrogenase
 galectins 93
 Gamimune N, purification 226
 Gammaguard, purification 224
 Gammunex, purification 224
 gastrointestinal (GI) disorders, Lewis blood group 89–90
 gastrointestinal (GI) infections
 ABO system 86–87
 P blood group system 97
 Sd^a antigen 99
 gastrointestinal (GI) tissue engineering 653–654
 GATA-binding factor 1 (GATA1) 159, 164
 GATA1 133, 135
 GATA1 *see* GATA-binding factor 1
 GBS *see* Guillain–Barré syndrome
 GBV-C (hepatitis G) 515
 GCNT2 (IGnT) 91–92
 GEF-H1 *see* guanine nucleotide exchange factor H1
 gel column testing 125
 gender, plasma composition 202
 gene editing 644
 gene therapy 642–647
 administration 642–643
 adverse effects 644
 gene editing 644
 hemophilia 434
 risks 643–644
 target selection and insertion 642, 643
 trials 644–646
 vaccinations 644
 vectors 643–644
 genetic regulation, megakaryopoiesis 164
 genetically engineered T cells 634
 genetics
 hemophilia 424–425
 I blood group 91–92
 LW system 107
 P blood group system 95–96
 Rh system 101–106
 genotyping
 human leukocyte antigens 629
 Rh system 105–106
 Gerbich blood group system 115, 329
 gestational thrombocytopenia (GT) 373–375
 GFI1 *see* growth factor interdependent 1
 GI *see* gastrointestinal
 GIL blood group system 114–115
 Glanzmann thrombasthenia 161
 GLOB 93
 glucose metabolism, red blood cells 145–148
 glucose-6-phosphate dehydrogenase (G6PD) deficiency 328–329, 337–338
 glutaminolysis, red blood cells 148
 glutathione, red blood cells 143, 148
 glycerolizing, red blood cells 156
 glycolysis 145
 glycophorin A and B *see* MNS blood group system
 glycophorin C and D *see* Gerbich blood group system
 glycosphingolipids (GSLs), P system 93–97
 glycosylphosphatidylinositol (GPI)-anchored blood groups 115–116
 good manufacturing practices 67–68
 Goodpasture syndrome (GPS), apheresis 272
 GPI *see* glycosylphosphatidylinositol
 GPS *see* Goodpasture syndrome
 graft-versus-host disease (GVHD), extracorporeal photopheresis 288–289
 Granix *see* TBO-filgrastim
 granulocytes 195–199
 administration, oncology patients 487
 adverse reactions to collection 54–55
 alloimmunization 487
 apheresis 195
 clinical recommendations 199
 collection 194–195, 487
 donor selection 194–195
 indications 486
 modification 487
 nonhemolytic transfusion reactions 566
 pediatric transfusions 198, 199
 prophylactic transfusions 198
 stimulation 195
 storage 195, 308, 487
 transfusion 195–198
 Group A *see* ABO system
 Group B *see* ABO system
 Group O, discovery of universality 8
 growth factor interdependent 1 (GFI1) 164
 GSLs *see* glycosphingolipids
 GT *see* gestational thrombocytopenia
 GTA *see* A-transferase
 GTB *see* B-transferase
 guanine nucleotide exchange factor H1 (GEF-H1) 164
 guanine nucleotides, red blood cells 148
 guidance documents, FDA, blood collection establishments 68–69
 guidelines
 perioperative practice 464–466
 red blood cell transfusions 322–324
 Guillain–Barré syndrome (GBS)
 apheresis 261, 266–267
 immunoglobulin therapy 245–246
 GVHD *see* graft-versus-host disease

 H antigen 81
 H gene 84–85
H. pylori *see* *Helicobacter pylori*
 H5N1 pandemic influenza 521
 HAA *see* hospital-acquired anemia
 Haemonetics MCS+ instrument 254
 Haemonetics PCS-2 instrument 254
 HAM test (acidified serum test) 360
 haplotypes, human leukocyte antigens 629
 Harvey, W. 3
 Hashimoto's encephalopathy, apheresis 269
 Hasse, O. 7
 HAV *see* hepatitis A
 HBV *see* hepatitis B
 HCV *see* hepatitis c
 HDFN *see* hemolytic disease of the fetus and newborn
 HDIVIG *see* high-dose intravenous immunoglobulin
 HDV *see* hepatitis D
 HE *see* hereditary elliptocytosis
 health emergencies 14–23
 absenteeism 16
 containment 22
 continuity of operations plans 17, 17
 COVID-19 14, 16, 18–23

- diagnostic testing 22
- epidemiological surveillance 22
- mitigation 22
- operations organization 15–16
- pandemic management 21–23
- preparedness 14–15, 16–17
- records management 18
- regulatory issues 17–18, 21–23
- therapeutics 23
- vaccines 23
- see also* disaster management
- heat treatment, virus inactivation 220
- heavy chains 119
- Helicobacter pylori* (*H. pylori*) 90
- HELLP syndrome *see* hemolysis, elevated liver enzymes, and low platelets
- hemagglutinins, levels allowable in immunoglobulin 226
- hemapheresis *see* apheresis; blood collection; blood components; plasma; source plasma
- hematologic disorders, therapeutic plasma exchange 269–272
- hematomas, blood donation 52
- hematopoiesis
 - acute radiation syndrome 611
 - Duffy protein 113
- hematopoietic development, I blood group 93
- hematopoietic growth factors 601–606, 601–616
 - erythroid 603–606
 - general principles 601–603
 - myeloid 606–611
 - thrombopoietic 611–616
- hematopoietic progenitor cells (HPC), adverse reactions 487–488
- hematopoietic stem cell transplants (HSCT)
 - oncology patients 482–483, 487–488
 - paroxysmal nocturnal hemoglobinuria 362
 - thalassemia 336
- hematopoietic stem cells (HSC) 617–623
 - ABO typing 620
 - collection 620–621
 - cord blood 621
 - COVID-19 622–623
 - cryopreservation 620–621
 - differentiation 133
 - dimethyl sulfoxide toxicity 565–566
 - erythropoiesis 133–134
 - infusion 622
 - megakaryopoiesis 158–160
 - microenvironment 617–619
 - mobilization 619–620
 - peripheral blood 620
 - regulations 623
 - storage 308
 - thawing 621–622
- hemoglobin
 - biosynthesis 135
 - gene editing 645
 - structural mutations 327–328
- hemoglobin C 327–328
- hemoglobin E 328
- hemoglobin S 47, 327
- hemolysis, mechanism 122
- hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome 373–374
- hemolytic disease of the fetus and newborn (HDFN) 106, 364–372
 - ABO system 85, 364–365
 - anemia 371
 - breast milk 371
 - care of newborn 368–371
 - care of sensitized pregnancies 368
 - D alloimmunization prevention 367–368
 - exchange transfusions 370–371
 - high-dose intravenous immunoglobulin 370, 378
 - hyperbilirubinemia 368–369
 - I blood group 92
 - immunology 365
 - Lutheran blood group 111
 - monitoring and management 365–368
 - necrotizing enterocolitis 371
 - phototherapy 369–370
 - primary prevention 367
 - simple transfusion 371
 - unexpected red blood cell antibodies 365
- hemolytic transfusion reactions 543–552
 - bystander hemolysis 547
 - causes 544–545
 - clinical features 547–550
 - complement 545–547
 - complications 550
 - diagnosis 547–550
 - immunoglobulin therapy 242–243
 - incidence 543–544
 - macrophages 547
 - pathophysiology 545–547
 - prevention 551–552
 - reticulocyte suppression/destruction 547
- hemolytic-uremic syndrome (HUS) 374–375
 - P blood group 97
- hemophilia 424–434
 - antifibrinolytics 432
 - clinical features 425
 - cryoprecipitate 426–427
 - cyclooxygenase 2 inhibitors 432
 - desmopressin 432
 - factor IX 431–432
 - factor VIII 427, **428–430**
 - gene editing 645
- gene therapy 434
- genetics 424–425
- immune tolerance induction 433–434
- inhibitory antibodies 432–433
- management 426–434
- prophylaxis 427
- vaccinations 432
- hemorrhage protocols, obstetric 376–377
- hemostasis
 - patient blood management 302–304
 - plasma 203
- hemostatic testing, preoperative 457–459
- hemovigilance 503–506
 - data analysis and assessment 504–506
 - events not captured 505
 - reporting systems 530–534
- heparin 251
- heparin re-exposure 417
- heparin-induced thrombocytopenia (HIT) 394, 413–417
 - argatroban 415–416
 - bivalirudin 416
 - contraindications 416–417
 - denaparoid sodium 416
 - fondaparinux 416
 - high-dose intravenous immunoglobulin 414–415
 - iceberg model 414
 - management 414–417
- hepatic toxicity, thrombopoietic growth factors 614
- hepatitis A (HAV) 507–508
 - discovery 9–10
 - neutropenia 192
 - testing 47
- hepatitis B (HBV) 508–511
 - diagnosis 510–511
 - discovery 9–10
 - neutropenia 192
 - pathogenesis 506–507
 - polyarteritis nodosa 272
 - testing 43–44
 - transmission 509–510
 - treatment 511
- Hepatitis B surface antigen (HBsAg) 44
- hepatitis C (HCV) 511–513
 - testing 44
 - thrombopoietic growth factors 614
 - treatment 511–513
- hepatitis D (HDV) 513–514
- hepatitis E (HEV) 514
- hepatitis F 515
- hepatitis G (GBV-C) 515
- hepcidin mimetics 596
- hereditary elliptocytosis (HE) 339
- hereditary hemochromatosis (HH), apheresis 284–285
- hereditary neutropenias 191–192
- hereditary pyropoikilocytosis (HPP) 339
- hereditary spherocytosis 338–339

- hereditary stomatocytoses 339
- hereditary xerocytosis (HX) 339
- HES *see* hydroxyethyl starch
- HEV *see* hepatitis E
- hexose monophosphate shunt (pentose shunt) 146, 147
- HH *see* hereditary hemochromatosis
- HHVs *see* human herpesviruses
- HIFs *see* hypoxia-inducible transcription factors
- high-dose intravenous immunoglobulin (HDIVIG)
 - hemolytic disease of the fetus and newborn 370, 378
 - heparin-induced thrombocytopenia 414–415
 - intravenous immunoglobulin 417
 - posttransfusion purpura 421
- histocompatibility testing *see* compatibility testing
- HIT *see* heparin-induced thrombocytopenia
- HLA *see* human leukocyte antigen; human leukocyte antigens
- HNA *see* human neutrophil antigens
- homology, Rh proteins 105
- homozygosity, Rh system 105, 106
- hormones, plasma composition 202–203
- hospital transfusion services
 - accreditation 73
 - adverse reaction reporting 70–73
 - defective product reporting 72
 - pretransfusion testing 122–130
 - sample collection 123–124
 - transfusion-related death reporting 71
 - United States regulations 70–73
 - World Health Organization programs 74–75
- hospital-acquired anemia (HAA) 461
- hospital-based tissue services 679
- HPA1a (PLA1) specific antigen, testing 47
- HPAs *see* human platelet antigens
- HPP *see* hereditary pyropoikilocytosis
- HSC *see* hematopoietic stem cells
- HTLV *see* human T-cell lymphotropic virus
- human herpesviruses (HHVs) 519
- human immunodeficiency virus (HIV) 515–517
 - antibody testing 43
 - confirmatory testing 43
 - erythroid growth factors 605
 - identification 10
 - neutropenia 192
 - nucleic acid tests 31, 43
 - P blood group 96
 - type 1 515–516
 - type 2 516–517
- human leukocyte antigen (HLA)-matched platelet transfusions 172–173, 399–400
- human leukocyte antigens (HLA) 624–632
 - antibody identification 630–632
 - antigens 625, 628
 - biological functions 625–626, 629
 - cross-reactive groups 172–173
 - disease associations 631–632
 - epitopes 631
 - genotyping 629
 - major histocompatibility complex 624–626
 - medical significance 629
 - next-generation sequencing 628
 - nomenclature 626–627
 - pharmacogenetics 632
 - phenotypes 629
 - platelets 168–169, 399–400
 - polymorphism 626–627
 - sequence-specific oligonucleotide probe hybridization 628
 - testing 47, 628–632
 - TRALI 575–576
 - transplantation 630–632
- human neutrophil antigens (HNA), TRALI 574–575
- human platelet antigens (HPAs) 169–170, 399–400
- human T-cell lymphotropic virus (HTLV) 516–517
 - testing 44
- human tissue allografts 670–683
 - ABO typing 672–673
 - acellular dermal matrix 675
 - adverse event monitoring 682
 - bone 673–674
 - cardiac 676–677
 - connective tissues 674–675
 - donor–recipient matching 672–673
 - general principles 670–672
 - ocular tissue 675–676
 - peripheral nerves 677
 - recalls and lookback 682–683
 - reimbursement 683
 - skin 675
 - surveillance 680–682
 - tissue processing 680
 - vascular tissue 676–677
- HUS *see* hemolytic uremic syndrome; hemolytic-uremic syndrome
- HX *see* hereditary xerocytosis
- hydroxyethyl starch (HES), therapeutic plasma exchange 263
- hyperbilirubinemia 368–369
- hypergammaglobulinemia, apheresis 270–271
- hyperhemolysis 343–344
- hyperimmune globulins 247–248
- hyperleukocytosis, apheresis 286
- hypocalcemia 257, 266
- hypodysfibrinogenemia 441–442
- hypofibrinogenemia 441
- hypokalemia 257
- hypotension
 - apheresis 257
 - transfusion reactions 565
- hypothermia 563
- hypoxia, erythropoietin regulation 136–137
- hypoxia-inducible transcription factors (HIFs) 136
- I blood group 90–93
 - biochemistry 91
 - biological roles 92–93
 - expression 90–91, 92–93
 - molecular biology 91–92
 - serology 90–91
 - transfusions 92
- I-null (i_{adult}) phenotype 91
- IAT *see* indirect antiglobulin test
- IC *see* informed consent
- ICAM-4 107
- iceberg model, heparin-induced thrombocytopenia 414
- ICL670Q *see* deferasirox
- idarucizumab 450
- IDE *see* iron-deficient erythropoiesis
- IGF1 *see* insulin-like growth factor-1
- IGnT (GCNT2) 91–92
- IL11 *see* interleukin-11
- immature platelet fraction (IPF) 167
- immediate, acute adverse reactions, blood donation 50
- immune responses 118–122
 - affinity maturation 119–120
 - antigen receptors 118
 - antigen-presenting cells 119
 - clonal selection 120
 - clonality 120
 - immunoglobulins 118–120
 - primary 119
 - secondary 119
 - somatic hypermutation 120
 - T-cell independent 119
- immune risk factors
 - ABO system 86–87
 - Lewis blood group 90
 - P blood group 93–94, 96–97
 - Sd^a antigen 99
- immune thrombocytopenic purpura (ITP) 393, 406–411
 - children 410–411
 - clinical features 406–407
 - danazol 410
 - emergency treatment 410
 - fostamatinib 409
 - immunoglobulin therapy 246
 - immunosuppression 409–410
 - intravenous immunoglobulin 407–408
 - monoclonal antibodies 409
 - pathogenesis 406
 - platelet lifespan 165–167
 - pregnancy 373–374, 410

- preoperative management 410
- preplatelet maturation 160–161
- reticulated platelets 166–167
- Rh immune globulin 408
- splenectomy 408–409
- thrombopoietic growth factors 614
- thrombopoietin receptor agonists 409
- treatment 407–411
- vinca alkaloids 410
- immune tolerance induction (ITI),
 - hemophilia 433–434
- immune-mediated thrombocytopenia 402–423
 - alloimmune 417–422
 - drug-induced 411–417
 - heparin-induced 413–417
 - immune thrombocytopenic purpura 406–411
 - laboratory tests 402–406
 - passive 421–422
 - posttransfusion purpura 421
 - refractoriness 422
 - vaccine-induced 417
 - see also* immune thrombocytopenic purpura; *individual disorders*. . .
- immunoabsorption, therapeutic plasma processing 275–276
- immunocompromised patients,
 - TA-GVHD 584
- immunodeficiency syndromes, TA-GVHD 583–584
- immunoglobulin A (IgA), deficiency
 - testing 47
- immunoglobulin G (IgG)
 - adverse reactions 242–243
 - affinity maturation 119–120
 - antibody structure 120
 - antiglobulin test 122
 - apheresis 260–261
 - depletion, source plasma donation 63
 - in plasma 201
 - primary immune responses 119
 - purification 238–240
 - secondary immune responses 119
 - transfusion 240–248
- immunoglobulin M (IgM)
 - antibody structure 120
 - antiglobulin test 122
 - in plasma 201
 - primary immune responses 119
 - T-cell independent response 119
- immunoglobulins
 - adverse reactions 242–243
 - affinity maturation 119–120
 - anticomplementary activity 226
 - autoimmune diseases 241, 245–247
 - autoimmune mucocutaneous bullous diseases 247
 - chronic inflammatory demyelinating polyneuropathy 246
 - complement scavenging 244
 - conventional-dose therapy 240
 - dosing and scheduling 244–247
 - drug interactions 241
 - European standards 226–227
 - Guillain–Barré syndrome 245–246
 - hyperimmune globulins 247–248
 - immune thrombocytopenic purpura 246
 - indirect actions 244
 - inflammatory diseases 241, 245–247
 - Kawasaki disease 245
 - mechanism of action 243–244
 - multifocal motor neuropathy 246–247
 - oncology patients 486
 - pathogen reduction 240, 496
 - plasma 201
 - primary immune deficiencies 244–245
 - products 236–248
 - purification 224–227, 238–240
 - secondary immune deficiencies 245
 - structure 118–119, 236–238, 238
 - subcutaneous therapy 240–241
 - transfusion-related acute lung injury 576
 - transplantation 247
 - warm autoimmune hemolytic anemia 350
 - see also* antibodies
- immunohematology 118–130
 - ABO typing 124
 - affinity maturation 119–120
 - agglutination 120–122
 - antibody–antigen interactions 120–122
 - antiglobulin tests 122, 124–125
 - automated testing 125–127, 128–129
 - compatibility testing 122–130
 - crossmatching 128–129
 - hemolysis 122
 - Rh typing 124–125
- immunosuppression
 - immune thrombocytopenic purpura 409–410
 - paroxysmal nocturnal hemoglobinuria 362
 - warm autoimmune hemolytic anemia 350
- immunotherapy
 - cancer 633, 636–637
 - chimeric antigen receptor T-cell therapy 634, 635–637
 - dendritic cells 638
 - donor lymphocyte infusions 633–634
 - genetically engineered T cells 634
 - mesenchymal stromal cells 639
 - regulatory T cells 634
 - tumor-infiltrating lymphocytes 634
 - viral infections 637–638
- implementation, patient blood management 293–294
- in vivo recovery, red blood cells 156–157
- in-date products, retrieval upon positive disease tests 42
- incidence *see* prevalence
- Indian blood group system 115
- indications
 - activated prothrombin complex concentrate 444
 - andexanet alfa 450
 - antifibrinolytics 447–448
 - cell salvage 301
 - cell-based immunotherapies 308
 - chimeric antigen receptor T-cell therapy 636–637
 - cryoprecipitate 308
 - desmopressin 448
 - granulocytes 308, 486
 - hematopoietic stem cells 308
 - idarucizumab 450
 - myeloid growth factors 606–609
 - plasma therapy 308
 - platelet therapy 307, 484
 - protamine 449
 - prothrombin complex concentrates 308, 443–444
 - recombinant activated factor VII 445
 - red blood cells 324
 - sickle cell disease 331–335, **332**
 - thalassemia 335–337
 - sickle cell disease 331–335, **332**
 - thalassemia 335–337
 - thrombopoietic growth factors 614–615
 - vitamin K 446
- indirect actions, immunoglobulins 244
- indirect antiglobulin test (IAT) 122, 124
- individual donor (IND) testing
 - HBV 43
 - HIV 43
- infants 381–391
 - anemia 381–382
 - coagulation system development 388–389
 - cryoprecipitate transfusions 390–391
 - granulocyte transfusions 198, **199**
 - paroxysmal nocturnal hemoglobinuria 363
 - plasma transfusions 388–390
 - platelet transfusions 385–388
 - preterm 382–383
 - red blood cell administration 322
 - red blood cell transfusions 382–383, 384–385
 - TRALI 573
 - see also* children; neonates
- infections
 - ABO system 86–87
 - Lewis blood group 90
 - neutropenia-causing 192–193
 - P blood group 93–94, 96–97
 - Sd^a antigen 99
 - see also* transfusion-transmitted infections

- inflammatory diseases, immunoglobulin therapy 241, 245–247
- inflammatory disorders, Lewis blood group 89–90
- influenza
 - pandemics 521
 - Sd^a antigen 99
- informed consent (IC)
 - donors 31–32
 - recipients 129
- inherited bleeding disorders 424–442
 - afibrinogenemia 441
 - combined factor V and factor VIII deficiency 438
 - dysfibrinogenemia 441–442
 - factor V deficiency 438
 - factor VII deficiency 438–439
 - factor X deficiency 439
 - factor XI deficiency 439–440
 - factor XIII deficiency 440–441
 - fibrinogen disorders 441
 - hemophilia 424–434
 - hypodysfibrinogenemia 441–442
 - hypofibrinogenemia 441
 - inherited bleeding disorders 424–442
 - pregnancy 375
 - prothrombin deficiency 437
 - von Willebrand disease 434–437
- inhibition, fibrinolysis 230
- inhibitory antibodies, hemophilia 432–433
- initiation, chelation 594
- iNKTs *see* invariant natural killer cells
- innate immunity, ABO system 87
- inosine 146–147
- INR *see* internationalized normalized ratio
- insertional mutagenesis 644
- inspections, blood collection
 - establishments 69
- insulin-like growth factor-1 (IGF1) 136
- integrins, LW system 107
- intensification of chelation 595
- interleukin-11 (IL11), oncology patients 486
- International Plasma Fractionation Association (IPFA) 78
- International Quality Plasma Program (IQPP) 34, 65
- International Society of Blood Transfusion (ISBT) 65, 78
- internationalized normalized ratio (INR) 457–458
- intracellular requirements, erythroid differentiation 135
- intravenous immunoglobulin (IVIG)
 - adverse reactions 242–243
 - anticomplementary activity 226
 - autoimmune mucocutaneous bullous diseases 247
 - chronic inflammatory demyelinating polyneuropathy 246
 - conventional dose therapy 240
 - dosing 244–247
 - drug interactions 241
 - drug-induced immune hemolytic anemia 357–358
 - European standards 226–227
 - Guillain-Barré syndrome 245–246
 - hemolytic disease of the fetus and newborn 370, 378
 - heparin-induced thrombocytopenia 414–415
 - high-dose therapy 241
 - hyperimmune globulins 247–248
 - immune thrombocytopenic purpura 246, 407–408
 - Kawasaki disease 245
 - mechanism of action 243–244
 - multifocal motor neuropathy 246–247
 - oncology patients 486
 - pathogen reduction 496
 - posttransfusion purpura 421
 - primary immune deficiencies 244–245
 - scheduling 244–247
 - secondary immune deficiencies 245
 - transplantation 247
 - vaccine-induced immune thrombotic thrombocytopenia 417
 - warm autoimmune hemolytic anemia 350
- intravenous (IV) access, venipuncture 307
- intrinsic pathway 204
- invariant natural killer cells (iNKTs) 82, 96
- inverse transfusion-related acute lung injury 576, 579
- IPF *see* immature platelet fraction
- IPFA *see* International Plasma Fractionation Association
- IQPP *see* International Quality Plasma Program
- iron burden
 - measurement 590–592
 - transfusional 589–590
- iron deficiency anemia (IDA) 56–64, 140–141
 - adverse outcomes 59–61
 - mitigation 61–62
 - neurocognitive effects 60
 - pica 60–61
 - pregnancy-related outcomes 60
 - prevalence in donors 56–58
 - regulation 58–59
 - restless legs syndrome 60
 - risk factors 56–58
 - vulnerable populations 61
- iron depletion
 - adverse outcomes 59–61
 - blood donors 56–62
 - mitigation 61–62
 - monitoring 61–62
 - neurocognitive effects 60
 - pica 60–61
 - pregnancy-related outcomes 60
- prevalence 56–58
- regulation 58–59
- restless legs syndrome 60
- risk factors 56–58
- vulnerable populations 61
- source plasma donors 63–64
- iron overload 344–345, 587–597
 - chelation 592–596
 - clinical features 590
 - erythroid maturation agents 596
 - fetal hemoglobin inducers 596
 - hepcidin mimetics 596
 - monitoring 345
 - novel approaches 596
 - pathophysiology 587–589
 - prevention 281
 - pyruvate kinase activators 596
 - transfusional iron burden 589–590
 - treatment 345, 592–596
- iron supplementation, donors 61
- iron-deficient erythropoiesis (IDE) 57
- irradiation
 - blood components 155, 186, 221, 309–310
 - plasma 221
 - platelets 186, 485
 - red blood cells 155, 483
- ISBT *see* International Society of Blood Transfusion
- issuance
 - blood components 307
 - cell-based immunotherapies 308
 - cryoprecipitate 308
 - granulocytes 308
 - hematopoietic stem cells 308
 - plasma 308
 - prothrombin complex concentrates 308
 - recombinant clotting factors 308
- issue dates 129
- ITI *see* immune tolerance induction
- ITP *see* immune thrombocytopenic purpura
- IVIG *see* intravenous immunoglobulin
- Jacobsen syndrome 161
- JR blood group system 116
- Kawasaki disease, immunoglobulin therapy 245
- Kell antigen, testing 47
- Kell blood group system 111–112
- Kidd blood group system 113–114
- kinetics
 - platelet production 165–167
 - red blood cell production 138
- kininogen 204–208
- KIOVIG, purification 224
- KLF-1 *see* Krüppel-like factor-1
- Knops blood group system 115, 330
- Kostmann syndrome 191
- Krüppel-like factor-1 (KLF-1) 134, 135

- L2 *see* deferiprone
 LacCer *see* lactosylceramide
 lactosylceramide (LacCer) 94
 LAD *see* leukocyte adhesion deficiency
 Lambert–Eaton myasthenic syndrome (LEMS), apheresis 267
 LAN blood group system 116
 Landsteiner, K. 7
 large volume delayed sampling 537
 LCMV *see* lymphatic choriomeningitis
 LDL apheresis 276
 leishmaniasis 527–528
 LEMS *see* Lambert–Eaton myasthenic syndrome
 lentiviruses, HIV 10, 31, 43, 96, 192, 515–517
 leukapheresis 54–55, 195
 leukemia, chimeric antigen receptor T-cell therapy 636
 Leukine *see* sargramostim
 leukocytophoresis 286
 leukocyte adhesion deficiency (LAD) syndromes 189
 leukocyte reduction (LR) 33, 309, 557–558
 platelets 186, 485
 red blood cells 155, 483
 Lewis blood group 87–90, 330
 biochemistry 87–88
 biological roles 89–90
 biosynthesis 87–88
 molecular biology 88–89
 nonsecretors 89
 serology 87
 transfusion considerations 89
 Lewis gene (*FUT3*) 88–89
 lifespan
 neutrophils 189
 platelets 165–167
 ligament allografts 674–675
 light chains 119
 liver biopsy
 plasma administration 467
 platelet administration 469
 LKE *see* luke antigen on erythrocytes
 loiasis, apheresis 289
 lookback 42, 683
 low income countries, obstetrics 378
 Lower, R. 4
 LR *see* leukocyte reduction
 luke antigen on erythrocytes (LKE) phenotype 93–94, 95, 96
 lumbar puncture
 plasma administration 468
 platelet administration 470
 lung allografts, rejection, extracorporeal photopheresis 288
 lung tissue engineering 648–650
 lusutrombopag (Mulpleta) 613
 Lutheran blood group system 111
 LW blood group system 107
 lymphatic choriomeningitis (LCMV) 521
 lymphocytes
 cancer treatment 633, 636–637
 chimeric antigen receptor-expressing 634, 635–637
 donor infusions 633–634
 genetically engineered 634–637
 infusions 633–634
 mesenchymal stromal cells 639
 natural killer cells 638–639
 regulatory T cells 634
 tumor-infiltrating 634
 viral infections 637–638
 lyophilization
 bone 673–674
 development of 9
 platelets 186–187
 M blood group system, discovery 8
 macrocytic anemia 138–140
 macrophages, hemolytic transfusion reactions 547
 macrothrombocytopenia syndromes, megakaryopoiesis pathologies 161
 major histocompatibility complex 624–626
 major obstetric bleeding 375–377
 malaria 326
 ABO system 86, 330
 red cell exchange 281–282
 transfusion-transmitted 526
 malignancies
 chimeric antigen receptor T-cell therapy 636–637
 thrombocytopenia 394
 see also cancer; oncology patients
 management
 hemolytic transfusion reactions 550
 PBM programs 293–305
 preoperative anemia 297–299
 see also treatment
 manual exchange transfusion, protocol 341
 manufacturing
 activated prothrombin complex concentrate 227–228, 444
 albumin 222–224
 alpha₂-proteinase inhibitor 228
 andexanet alfa 450
 antifibrinolytics 447
 antithrombin III 230
 C1 inhibitor 229–230
 desmopressin 448
 factor IX 232
 factor VIII 233–234
 factor X 227
 factor XI 228–229
 factor XIII 227
 fibrinogen 231
 immunoglobulins 224–227, 238–240
 protamine 449
 prothrombin complex concentrate 231–232
 prothrombin complex concentrates 443
 recombinant activated factor VII 445
 vitamin K 446
 von Willebrand factor 232–233
 mass casualty events
 administration 478
 preparedness 16
 massive transfusion protocols (MTP) complications 561–564
 obstetrics 376–377
 maternal thrombocytopenia 374–375
 matrix metalloproteinases (MMP), platelet production 160, 165
 maturation, megakaryocytes 159–161
 May–Hegglin anomaly 161
 MB *see* methylene blue
 MDDS *see* Medical Device Data Systems
 Medical Device Data Systems (MDDS) 70
 medication coadministration 311–312
 medicines safety monitoring, Europe 77
 megakaryocyte-erythroid precursors (MEPs) 159
 megakaryocytes (MKs)
 differentiation 158–165
 maturation 159–161
 migration 158–159
 platelet formation 161–162
 megakaryocytic-erythroid progenitor (MEP) 133–134
 megakaryopoiesis 158–165
 biophysical niche forces 164–165
 cytokines 162–164
 differentiation 158–161
 genetic regulation 164
 pathologies 161–162
 platelet formation 161–162
 proliferation 158
 regulation 162–165
 thrombopoietin 158–160, 162–164
 melanoma, I blood group 93
 membrane complex, Rh system 104–105
 membrane elongation, protoplatelets 160
 membrane metabolism, red blood cells 149–150
 membrane mutations, red blood cells 329, 338–339
 membrane topology, Rh system proteins 102
 men who have sex with men (MSM), screening 31
 meniscus allografts 674
 mental stress, plasma composition 202–203
 MEP *see* megakaryocytic-erythroid progenitor
 MEPs *see* megakaryocyte-erythroid precursors
 MER2 116
 mesenchymal stem cells, I blood group 93
 mesenchymal stromal cell (MSC) immunotherapy 639

- mesenchymal–epithelial transition (MET) 89, 93, 96
 MET *see* mesenchymal–epithelial transition
 metabolic alkalosis 257, 266
 metabolism
 platelets 181–183
 red blood cells 143–150
 methoxy polyethylene glycol-epoetin beta (Micera) 604
 N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis 267
 methylene blue (MB) pathogen reduction 493, 496, 500
 MGUS *see* monoclonal gammopathy of unknown significance
 Micera *see* methoxy polyethylene glycol-epoetin beta
 microaggregate debris 563
 microangiopathic hemolytic anemias 393–394
 microcirculatory effects, anemia 316–317
 microcytic anemia 140–141
 microfilariasis 528–529
 microtubules, protoplatelets 160
 migration
 megakaryocytes 158–159
 neutrophils 189
 milk, as a blood substitute 7
 mini physical exam 32, 34–35
 minipools, HIV testing 43
 minor blood group antigens
 DNA-based typing 127–128, 129
 see also protein blood groups
 mitigation
 disaster management 14–15
 donation-related iron depletion 61–62, 63
 health emergencies 22
 mixed autoantibody hemolytic anemia 355–356
 MKL1 and MKL2 *see* myocardin-like transcription factors
 MM *see* multiple myeloma
 MMN *see* multifocal motor neuropathy
 MMP *see* matrix metalloproteinases
 MNS blood group system 109–111, 110, 330
 discovery 8
 mobilization
 hematopoietic stem cells 619–620
 neutrophils 188–189
 peripheral blood progenitor cells 610–611
 modern transfusion
 beginnings 5–7
 twentieth century 7–8
 modifications
 aliquoting 310
 granulocytes 487
 irradiation 155, 186, 221, 309–310
 leukocyte reduction 33, 155, 186, 309
 platelets 185–186, 485
 red blood cells 483
 washing 155, 186, 310
 molecular biology
 ABO system 83–85
 human leukocyte antigens 625–626
 I blood group 91–92
 Lewis blood group 88–89
 P blood group 95–96
 prions 529–530
 Sd^a antigen 97–98
 molecular structure
 ABO antigens 81–84
 antibodies 120
 Diego antigens 110, 114
 Duffy protein 112–113
 I group antigens 91
 immunoglobulins 118–119, 236–238, 238
 Kell–XK complex 111–112
 Lutheran antigens 111
 MNS antigens 110
 P group antigens 93–94
 Rh antibodies 107
 Rh proteins 100–105
 monitoring
 chelation 595–596
 hemolytic disease of the fetus and newborn 365–368
 human tissue allografts 680–683
 iron overload 345
 physicians 295–297
 red blood cell administration 341–342
 monoclonal antibodies 120
 cold agglutinin disease 353
 immune thrombocytopenic purpura 409
 interference in pretransfusion testing 127
 paroxysmal nocturnal hemoglobinuria 361–362
 warm autoimmune hemolytic anemia 350
 monoclonal gammopathy of unknown significance (MGUS), apheresis 268
 monocytes, transfusion-related acute lung injury 574
 MonoMAC syndrome 192
 MPL gene 161
 MPPs *see* multipotent progenitors
 MS *see* multiple sclerosis
 MSC *see* mesenchymal stromal cell
 MSM *see* men who have sex with men
 MTP *see* massive transfusion protocols
 mucinous A 82
 Mudd, S. 9
 Mulpleta *see* lusutrombopag
 multicomponent collections, apheresis 253, 256
 multifocal motor neuropathy (MMN), immunoglobulin therapy 246–247
 multiple component collection, adverse reactions 54
 multiple myeloma, apheresis 273
 multiple sclerosis (MS), apheresis 268
 multipotent progenitors (MPPs) 133
 Murphy, W.P. 9
 mushroom poisoning, apheresis 273
 myasthenia gravis, apheresis 267
 myelodysplastic syndrome (MDS) 615
 myeloid growth factors 606–611
 adverse effects 608–609
 indications 606–609
 myeloid transcription factors 133, 135
 Myelokathexis 191
 myeloma cast nephropathy, apheresis 273
 myocardin-like transcription factors (MKL1/MKL2) 164
 N blood group system
 discovery 8
 see also MNS blood group system
 NAIT *see* neonatal alloimmune thrombocytopenia
 NAT *see* nucleic acid testing
 NATA *see* Network for Advancement of Transfusion Alternatives
 national authorities, disaster management 18
 National Blood Collection and Utilization Survey (NBCUS) 29
 national competent authorities (NCAs) 77
 National Regulatory Authorities (NRAs) 75
 National Response Framework (NRF) 16
 natural killer (NK) cell immunotherapy 638–639
 NBCUS *see* National Blood Collection and Utilization Survey
 NCAs *see* national competent authorities
 NEC *see* necrotizing enterocolitis
 necrotizing enterocolitis (NEC)
 hemolytic disease of the fetus and newborn 371
 Lewis blood group 89–90
 neonatal alloimmune neutropenia 192
 neonatal alloimmune thrombocytopenia (NAIT) 29, 385, 395, 419–421
 neonatal treatment 420
 prenatal management 420–421
 neonatal thrombocytopenia 385
 neonates
 hyperbilirubinemia 368–369
 I blood group 90–93
 phototherapy 369–370
 testing, HDFN 368
 TRALI 573
 nerve injuries, blood donation 53
 NETosis 189–190

- Network for Advancement of Transfusion Alternatives (NATA) 293
 Neulasta *see* pegfilgrastim
 Neupogen *see* filgrastim
 neurocognitive effects, iron deficiency anemia 60
 neurological disorders, therapeutic plasma exchange 266–269
 neuromyelitis optica spectrum disorder (NMOSD), apheresis 268–269
 neurosurgical procedures
 plasma administration 468
 platelet administration 470
 neutropenias 190–193
 adult 192–193
 congenital 191–192
 medications causing 192
 myeloid growth factors 609–611
 neutrophilia 190
 neutrophils 188–193
 clearance 189
 kinetics 188–190
 migration 189
 mobilization 188–189
 NETosis 189–190
 production 188
 transfusion-related acute lung injury 573–574
 next-generation sequencing (NGS) 628
 NGS *see* next-generation sequencing
 nineteenth century
 animal-to-human transfusions 7
 anticoagulants 6–7
 modern transfusion development 5–7
 saline solutions 7
 nitric oxide, synthesis, red blood cells 149
 Nivestym *see* filgrastim-aafi
 NK *see* natural killer
 NMDAR *see* N-methyl-D-aspartate receptor
 NMOSD *see* neuromyelitis optica spectrum disorder
 nomogram 35
 nonantibody transfusion-related acute lung injury 576, 579
 nonengineered T-cell
 immunotherapies 633–634
 nonhematopoietic cells, apheresis 289
 nonhemolytic transfusion reactions 553–568, 567
 allergic responses 558–561
 anaphylaxis/anaphylactoid reactions 559–561
 autologous transfusions 566
 circulatory overload 215, 310, 563–564
 dimethyl sulfoxide toxicity 565–566
 electrolyte disorders 562–563
 febrile 553–558
 granulocytes 566
 hypotensive 565
 hypothermia 563
 microaggregate debris 563
 plasticizer toxicity 565
 nonsecretors, Lewis blood group 89
 nonsteroidal anti-inflammatory drugs (NSAIDs), thrombocytopenia 394
 NOR phenotype 95
 Nplate *see* Romiplostim
 NRAs *see* National Regulatory Authorities
 NRF *see* National Response Framework
 NSAIDs *see* nonsteroidal anti-inflammatory drugs
 nuclear agent attacks 16
 nucleic acid testing (NAT) 39
 babesiosis 45
 bacterial contamination 538
 HBV 44
 HCV 44
 HIV 43
 HIV screening 31
 syphilis 45
 West Nile virus 45
 Zika virus 45
 see also polymerase chain reaction; transcription-mediated amplification
 nutritional requirements, erythropoiesis 138–142
 Nyvepria *see* pegfilgrastim-apgf

 O antigen 81
 OBRR *see* Office of Blood Research and Review
 obstetrics 373–380
 antifibrinolytics 377
 antiphospholipid antibody syndrome 375
 chronic anemia 375
 disseminated intravascular coagulation 375
 fetal administration 379–380
 fetal/neonatal alloimmune thrombocytopenia 379–380
 fibrinogen concentrates 377
 gestational thrombocytopenia 373–375
 HELLP syndrome 373–374
 hemolytic-uremic syndrome 374–375
 hemorrhage protocols 376–377
 immune thrombocytopenic purpura 373–374
 inherited bleeding disorders 375
 low income countries 378
 postpartum anemia 377–378
 thrombotic thrombocytopenic purpura 374–375
 transfusions 375–380
 see also pregnancy
 octanoic acid (caprylate) treatment, plasma 221
 Octagam, purification 224
 ocular tissue allografts 675–676

 Office of Blood Research and Review (OBRR) 68
 Office of Tissues and Advanced Therapies (OTAT) 68
 Official Medicines Control Laboratory (OMCL) 77
 OHSt *see* overhydrated hereditary stomatocytosis
 OK blood group system 116
 OMCL *see* Official Medicines Control Laboratory
 Oncley process, immunoglobulins 224–226
 oncology patients 482–488
 adverse reactions 487–488
 chimeric antigen receptor T-cell therapy 488, 636–637
 erythroid growth factors 605
 granulocyte transfusions 486–487
 hematopoietic stem cell transplants 482–483, 487–488
 platelet transfusions 484–486
 red blood cell administration 322, 482–484
 risk factors 487
 T-cell immunotherapies 633
 see also cancer
 operations organization, disaster management 15–16
 ophthalmological complications, sickle cell disease 335
 oral calcium supplementation, apheresis 54
 organization
 emergency operations 15–16
 patient blood management 293–305
 United States blood services 12
 worldwide blood services 12–13
 orthochromatic erythroblasts (OrthoEBs) 134
 orthopedic surgery, red blood cell administration 321
 OTAT *see* Office of Tissues and Advanced Therapies
 OthoEBs *see* orthochromatic erythroblasts
 Ottenberg, R. 8
 overdose, apheresis 273
 overhydrated hereditary stomatocytosis (OHSt) 339
 oversight, human tissue allografts 677–678

 P blood group system 93–97
 biochemistry 93–94
 biosynthesis 93–94
 discovery 8
 epitopes 93–94
 expression 93–94, 96
 genetics 95–96
 molecular biology 95–96
 serology 94–95
 transfusions 96

- P. falciparum* *see Plasmodium falciparum*
 p null phenotype 94–95
 P synthase (*B3GALNT1*) 94, 95
 P1PK synthase (*A4GALT1*) 94, 95
 p14 deficiency syndrome 192
 packed red blood cells (PRBCs)
 collection 32
 separation 32
 PAH *see* pulmonary arterial hypertension
 PAN *see* polyarteritis nodosa
 PANDAS *see* pediatric autoimmune
 neuropsychiatric disorders
 associated with streptococcal
 infections
 pandemic influenza 521
 pandemic management 21–23
 panel-reactive antibody (PRA) tests
 630–631
 paracentesis
 plasma administration 468
 platelet administration 469
 paraproteinemic demyelinating
 polyneuropathies, apheresis 268
 Paris–Trousseau thrombocytopenia 161
 paroxysmal cold hemoglobinuria (PCH)
 96, 354–355
 paroxysmal nocturnal hemoglobinuria
 (PNH) 358–363
 anticoagulants 360
 bone marrow disorders 363
 children 363
 clinical features 359–360
 eculizumab 361–362
 elective surgery 363
 epidemiology 358
 hematopoietic stem cell transplants 362
 immunosuppression 362
 pathophysiology 358–359
 pregnancy 363
 prognosis 363
 red blood cell administration 362–363
 risk factors 358
 treatment 360–363
 partial D phenotype 102, 105–106
 Parvovirus B19 519–520
 aplastic crisis 333–334
 P blood group system 96
 testing 47
 passive alloimmune thrombocytopenia
 (PAT) 421–422
 PAT *see* passive alloimmune
 thrombocytopenia
 pathogen reduced plasma 210, 219–221,
 495–496
 pathogen reduction 489–500
 albumin 496
 alloimmunization 498–499
 amotosalen/UV-A 490, 492, 495, 497,
 498, 499
 amustaline/glutathione 492–493, 496,
 499–500
 bacterial contamination 538–539
 efficacy 493–495
 fresh frozen plasma 495–496
 immunoglobulins 240, 496
 immunological effects 498–499
 methylene blue 493, 496, 500
 overview 489–490
 platelets 496–499
 red blood cells 155, 498
 riboflavin/UV 492, 495, 497, 498, 499
 safety and toxicity considerations
 499–500
 solvent and detergent 493, 496, 500
 technologies 490–493
 transfusion-associated graft-versus-host
 disease 499
 ultraviolet C 493, 496, 497, 500
 in vitro platelet function 496–497
 in vivo function tests 497–498
 pathogenesis
 alloimmune thrombocytopenia 417
 heparin-induced thrombocytopenia
 414–415
 hepatitis B 506–507
 immune thrombocytopenic
 purpura 406
 posttransfusion purpura 421
 pathophysiology
 anemia 137, 381–382
 cold agglutinin disease 351–352
 drug-induced immune hemolytic
 anemia 356–357
 hemolytic transfusion reactions
 545–547
 iron overload 587–589
 paroxysmal cold hemoglobinuria 354
 paroxysmal nocturnal
 hemoglobinuria 358–359
 sickle cell disease 330–331
 transfusion-associated graft-versus-host
 disease 582
 transfusion-related acute lung injury
 570–571, 573–577
 warm autoimmune hemolytic anemia
 346–348
 patient blood management (PBM) 293–305
 acute nonvolemic hemodilution
 301–302
 antifibrinolytics 303
 cell salvage 299–301
 definitions 293
 desmopressin 303–304
 evidence-based guidelines 294–295
 fibrinogen concentrates 304
 hemostatic agents 302–304
 limiting phlebotomy blood loss 304
 physician education and monitoring
 295–297
 point-of-care testing 302
 preoperative anemia management
 297–299
 program implementation 293–294
 prothrombin complex concentrates 303
 recombinant activated factor VII 304
 washed cell salvage 300–301
 patient monitoring 312
 patient safety organizations (PSOs) 129
 PBM *see* patient blood management
 PBSC *see* peripheral blood stem cell
 PCC *see* prothrombin complex
 concentrates
 PCH *see* paroxysmal cold hemoglobinuria
 PCR *see* polymerase chain reaction
 pediatric. . . , *see also* children; infants;
 neonates
 pediatric autoimmune neuropsychiatric
 disorders associated with
 streptococcal infections (PANDAS),
 apheresis 269
 pegfilgrastim (Neulasta) 607
 pegfilgrastim-apgf (Nyvepria) 608
 pegfilgrastim-bmez (Ziextenzo) 608
 pegfilgrastim-cbqv (Udenyca) 608
 pegfilgrastim-jmdb (Fulphilia) 608
 PEL blood group system 116–117
 pentose shunt (hexose monophosphate
 shunt) 146, 147
 perioperative practice 453–471
 acute nonvolemic hemodilution 462
 anemia 453–455
 anticoagulants 459–460
 anticoagulation therapies 459–461
 antiplatelet therapies 459–461
 blood avoidance techniques 461–462
 conservative practice 461
 direct oral anticoagulants 460
 guidelines 464–466
 paroxysmal nocturnal
 hemoglobinuria 363
 plasma administration 464–470
 platelet administration 466,
 469–470
 point-of-care viscoelastic assays 459
 red blood cell administration 464
 topical hemostatic therapies 462–463
 peripheral blood progenitor cell
 mobilization 610–611
 peripheral blood stem cell (PBSC)
 collection 620
 peripheral nerve allografts 677
 peripheral nerve system tissue engineering
 651–652
 pH
 albumin 223
 alpha₁-proteinase inhibitor 228
 antithrombin III 230
 factor IX 232
 fibrinogen 231
 immunoglobulins 226
 platelet storage 182–183
 prothrombin complex concentrate 232
 red blood cell storage 153

- virus inactivation 221
 - von Willebrand factor 233
 - pharmacogenetics, human leukocyte antigens 632
 - phenotypes, human leukocyte antigens 629
 - PhEur *see* European Pharmacopeia
 - phlebotomy
 - donor collections 32–36
 - acute adverse reactions 52–53
 - limiting blood loss 304
 - pretransfusion testing 123–124
 - see also* blood collection
 - phlebotomy-related nerve injury, donors 53
 - photochemotherapy *see* extracorporeal photopheresis
 - phototherapy, hemolytic disease of the fetus and newborn 369–370
 - PHSA *see* Public Health Service Act
 - physical examination
 - blood donors 32
 - source plasma donors 34–35
 - physical exercise, plasma composition 202
 - physician education 295–297
 - physician monitoring 295–297
 - phytanic acid storage disease, apheresis 269
 - pica, donation-related iron deficiency 60–61
 - P^k phenotype 94
 - PKD *see* pyruvate kinase deficiency
 - PLA1 *see* HPA1a
 - planning, disaster management 14–15, 16–17
 - plasma 200–235
 - ABO antibody titers 38–39
 - administration 209–215
 - adverse reactions 215
 - angiography 468–469
 - bleeding treatment 212–213
 - bronchoscopy 468
 - burn patients 480
 - central venous catheter insertions 466–467
 - children 388–390
 - clinical use 212
 - combined factor V and factor VIII deficiency 438
 - cryoprecipitate 214–215
 - disseminated intravascular coagulation 213
 - epidural anesthesia 468
 - factor V deficiency 438
 - hemophilia 426–427
 - infants 388–390
 - liver biopsy 467
 - lumbar puncture 468
 - neurosurgical procedures 468
 - oncology patients 486
 - paracentesis 468
 - perioperative guidelines 464–466
 - prophylactic 213–214
 - prothrombin deficiency 437
 - thoracentesis 468
 - transbronchial lung biopsy 468
 - trauma patients 480
 - upper airway procedures 468
 - warfarin effect 214
 - adverse reactions 215
 - albumin 200
 - alpha-1 antitrypsin 201
 - alternate preparations 209–211
 - apheresis collection requirements 254–255
 - bacterial contamination 541
 - C1 inhibitor 201
 - chromatographic separation 218–219, 222
 - clotting factors 201–202, 210–211
 - coagulation factor inhibitors 201–202, 203
 - coagulation screening tests 204–208
 - cold ethanol fractionation 9, 217–218
 - collection
 - chronic effects 63–64
 - donor screening 34–35, 37, 39–47
 - process 34–36
 - composition 200–208
 - convalescent 23, 212
 - cryoprecipitate 210–211, 214–215
 - donor screening 34–35, 37, 39–47
 - dried 209–210
 - European regulation 75–78
 - fibrinolysis 203–208
 - frozen storage 203
 - hemostasis 203
 - immunoglobulins 201
 - infectious disease testing 37, 39–47
 - see also* prerelease testing
 - initial usage 9
 - medicinal product manufacturing processes 222–234
 - octanoic acid treatment 221
 - pathogen reduced 210, 219–221, 495–496
 - pH 221
 - prion safety 222
 - protein purification 216–235
 - separation 33
 - solvent and detergent treatment 33, 220–221
 - storage 203
 - thawing 311
 - ultraviolet treatment 221
 - virus filtration 221
 - virus inactivation 220–221
 - volume reduction 310
 - von Willebrand factor 201–202
 - World Health Organization programs 74–75
 - see also* source plasma; therapeutic plasma exchange
- plasma composition, acute phase reaction 202
 - plasma exchange *see* therapeutic plasma exchange
 - Plasma Protein Therapeutics Association (PPTA) 65, 78
 - Plasma Protein Therapeutics Association (PPTA)-certified centers 34
 - plasma removal, platelets 186
 - plasma-derived factor FVII (pdFVII) 438–439
 - plasma-derived medicinal products (PDMPs) 12, 216–235
 - activated prothrombin complex concentrate 227–228
 - albumin 222–224
 - alpha₁-proteinase inhibitor 228
 - antithrombin III 230
 - bacterial contamination 541
 - C1 inhibitor 229–230
 - chromatographic separation 218–219, 222
 - cold ethanol fractionation 217–218
 - European regulation 77
 - factor IX 232
 - factor VIII 233–234
 - factor X 227
 - factor XI 228–229
 - factor XIII 227
 - fibrinogen 231
 - heat treatment 220
 - immunoglobulins 224–227
 - octanoic acid treatment 221
 - oncology patients 486
 - pathogen reduction 219–221
 - pH 221
 - prion safety 222
 - prothrombin complex concentrate 231–232
 - purifications 222–234
 - solvent and detergent treatment 220–221
 - ultraviolet treatment 221
 - validation of virus reduction/removal 219–220
 - virus filtration 221
 - virus inactivation 220–221
 - virus reduction 219–220
 - von Willebrand factor 232–233
 - plasmapheresis
 - anticoagulants 251–252
 - see also* therapeutic plasma exchange
 - Plasmodium falciparum* (*P. falciparum*) 86, 281–282, 330
 - plasticizer toxicity 565
 - platelet-rich plasma (PRP) 179
 - separation 33
 - plateletpheresis 180
 - acute adverse reactions 53–54
 - chronic effects 63
 - requirements 255–256
 - thrombocytosis 285–286

- platelets 158–187
 - ABO system antigens 170–171, 484
 - acquired disorders 393
 - additive solutions 184–185
 - administration 395–400
 - bronchoscopy 469
 - cardiac surgery 470
 - central venous catheter placement 469
 - children 385–388
 - dosing 397
 - epidural anesthesia 470
 - fetal 379
 - infants 385–388
 - liver biopsy 469
 - lumbar puncture 470
 - maternal 378
 - neurosurgical procedures 470
 - oncology patients 484–486
 - paracentesis 469
 - perioperative guidelines 464–466
 - preoperative 397–398
 - prophylactic 396–397
 - refractoriness 398–399, 422
 - therapeutic 398–400
 - thoracentesis 469
 - transbronchial lung biopsy 469
 - upper airway procedures 469
 - alloimmunization 171–177, 399–400, 485, 498–499
 - alternate sources 181
 - antibody-specific prediction 173–174
 - antigen typing 47, 399
 - antigens 168–171, **418**
 - apheresis-derived 180
 - bacterial contamination 46, 533–539
 - buffy-coat method 180
 - centrifugation 186
 - circulatory survival 165
 - congenital disorders 393
 - crossmatching 174, 400, 484
 - differentiation 158–165
 - HLA-matched transfusions 172–173
 - human leukocyte antigen 168–169, 399–400
 - human platelet antigens 169–170, 399
 - immunology 168–177
 - irradiation 186, 485
 - issuance 307
 - kinetics 165–167
 - leukocyte reduction 186, 485
 - lifespan 165–167
 - megakaryopoiesis regulation 162–165
 - modifications 185–186
 - novel storage techniques 186–187
 - oncology patients 484
 - pathogen reduction 496–499
 - pathologies of megakaryopoiesis 161–162
 - plasma removal 186
 - platelet-rich plasma 179
 - preoperative transfusions 397–398
 - preparation 179–181
 - prevention of alloimmunization 176–177
 - production 158–165
 - prophylactic transfusions 396–397
 - refractoriness 174, 398–399, 422, 485
 - sequestration 167, 392–393
 - storage 181–187, 307
 - additive solutions 184–185
 - containers 183
 - lesions 183–184
 - metabolic needs 181–183
 - pH 182–183
 - respiratory capacity 183
 - temperature 181–182
 - transfusion-related acute lung injury 574
 - volume reduction 186, 310, 485
 - washing 186
- PNH *see* paroxysmal nocturnal hemoglobinuria
- point of care immunoassays, bacterial contamination 537–538
- point-of-care assays, viscoelastic 459
- point-of-care testing 302
- polyamines, red blood cells 148–149
- polyarteritis nodosa (PAN), apheresis 272
- polychromatophilic erythroblasts (PolyEBs) 134
- polycythemia vera, apheresis 282–283
- PolyEBs *see* polychromatophilic erythroblasts
- polymerase chain reaction (PCR) testing 39
 - human leukocyte antigens 628
- polymorphism in human leukocyte antigens 626–627
- pooled plasma, TRALI prevention 578–579
- pooling
 - HIV testing 43
 - nucleic acid testing 39
- post-transfusion sepsis, prevention strategies 535–540
- postdonation care 32–33
- postpartum anemia 377–378
- posttransfusion purpura (PTP) 395, 421
- PPTA *see* Plasma Protein Therapeutics Association
- PRA *see* panel-reactive antibody tests
- PRBCs *see* packed red blood cells
- pregnancy 373–380
 - antiphospholipid antibody syndrome 375
 - blood donation 33
 - chronic anemia 375
 - disseminated intravascular coagulation 375
 - donation-related iron deficiency 60
 - fetal administration 379–380
 - fetal/neonatal alloimmune thrombocytopenia 379–380
 - gestational thrombocytopenia 373–375
 - HELLP syndrome 373–374
 - hemolytic disease of the fetus and newborn 364–372
 - hemolytic-uremic syndrome 374–375
 - hemorrhage protocols 376–377
 - immune thrombocytopenic purpura 373–374, 410
 - inherited bleeding disorders 375
 - low income countries 378
 - paroxysmal nocturnal hemoglobinuria 363
 - platelet transfusions 378
 - postpartum anemia 377–378
 - red blood cells transfusions 378
 - red cell exchange 281, 334
 - sickle cell disease 334
 - thrombotic thrombocytopenic purpura 374–375
 - transfusions 375–380
- prekallikrein 205–208
- prenatal genotyping, Rh proteins 105
- preoperative anemia
 - erythroid growth factors 605
 - management 297–299, 454–455
- preoperative hemostatic testing 457–459
- preoperative intravenous immunoglobulin, immune thrombocytopenic purpura 410
- preoperative platelet transfusions 397–398
- preoperative red cell exchange 281, 334
- preparation
 - blood components 309–311
 - irradiation 309–310
 - leukocyte reduction 309
 - platelets 179–181
 - thawing plasma 311
 - washing 310
- preparedness, disaster management 14–15, 16–17
- preplatelets 160–161
- prerelease testing 39–47
 - babesiosis 45
 - blood derivatives 46
 - Chagas' disease 46
 - cytomegalovirus 46
 - donated blood 39, **40**
 - donor management 41–42, **41**
 - donor reentry **41**, 42–43
 - extended blood group antigen typing 47
 - false positives 39
 - hemoglobin S 47
 - hepatitis A 47
 - hepatitis B 43–44
 - hepatitis C 44
 - HIV 43

- human leukocyte antigen 47
- human T-cell lymphotropic virus 44
- IgA deficiency 47
- lookback 42
- Parvovirus B19 47
- platelet antigen typing 47
- platelets 46
- pooling 39, 43
- product management 42
- recipient notification 42
- regulations 39–40, 41–42
- resource-limited settings 40
- sequence 40
- syphilis 45–46
- West Nile virus 45
- Zika virus 45
- preservation
 - cell-based immunotherapies 308
 - cryoprecipitate 308
 - granulocytes 195, 308
 - hematopoietic stem cells 308
 - plasma 308
 - platelets 181–187, 307
 - additive solutions 184–185
 - containers 183
 - cryopreservation 186
 - lesions 183–184
 - lyophilization 186–187
 - metabolic needs 181–183
 - pH 182–183
 - respiratory capacity 183
 - temperature 181–182, 186
 - red blood cells 150–157, 307
 - additive solutions 152–154
 - anticoagulant-nutrient solutions 152
 - effectiveness 155–156
 - frozen storage 156
 - leukocyte reduction 155
 - pathogen reduction 155
 - pH 153
 - principles 150–151
 - rejuvenation 156
 - storage containers 154–155
 - temperature and time lapse 154
 - washing 155
- presyncopal symptoms, blood donation 50
- preterm infants, red blood cell transfusions 382–383
- pretransfusion checks at bedside 311
- pretransfusion testing 118–130
 - ABO typing 124
 - administration 129
 - antiglobulin tests 129
 - automation 125–127, 128–129
 - biochemistry 118–122
 - blood selection 128
 - compatibility testing 122–130
 - crossmatching 128–129
 - DNA-based blood group typing 127–128, 129
 - donor testing 122–123
 - donor–recipient 128–129
 - emergency release 129
 - issue dates 129
 - minor blood group antigens 127–128, 129
 - monoclonal antibody interference 127
 - patient testing 123–130
 - prior records checking 128–129
 - red blood cells 339–340
 - sample collection 123–124
 - unit labeling 129
- prevalence
 - alloimmune
 - thrombocytopenia 418–419
 - cold autoimmune hemolytic anemia 351
 - donation-related iron depletion 56–58
 - drug-induced immune hemolytic anemia 356
 - hemolytic transfusion reactions 543–544
 - paroxysmal nocturnal hemoglobinuria 358
 - paroxysmal cold hemoglobinuria 354
 - therapeutic plasma exchange complications 264–265
 - transfusion-associated graft-versus-host disease 583
 - transfusion-related acute lung injury 572–573
 - transfusion-related circulatory overload 580
 - warm autoimmune hemolytic anemia 346
- prevention
 - allergic responses 559
 - alloimmunization 176–177
 - anaphylaxis 561
 - febrile nonhemolytic reactions 557–558
 - hemolytic disease of the fetus and newborn 367–368
 - hemolytic transfusion reactions 551–552, 557–558
 - post-transfusion sepsis 535–540
 - stroke, sickle cell disease 332–333
 - syncopal reactions, blood donation 51–52
 - transfusion-associated graft-versus-host disease 585–586
 - transfusion-related circulatory overload 580
- primary immune deficiencies, immunoglobulins 244244–244245
- primary immune responses 119
- primary stroke prevention, red cell exchange 280–281, 332–333
- primary thrombocytosis, apheresis 285–286
- prions 11, 31, 222, 529–531
 - molecular biology 529–530
 - regulatory measures 531
 - transmissibility 530–531
- Privigen, purification 226
- procedure requirements, apheresis, collections 254–256
- Procrit *see* epoetin alfa
- product requirements, apheresis, collections 254–256
- ProEBs *see* proerythroblasts
- proerythroblasts (ProEBs) 134
- prognoses
 - cold agglutinin disease 354
 - paroxysmal cold hemoglobinuria 355
 - paroxysmal nocturnal hemoglobinuria 363
 - warm autoimmune hemolytic anemia 351
- programmed cell death, red blood cells 150
- proliferation, megakaryocytes 158
- Promacta *see* eltrombopag
- prophylactic transfusions
 - granulocytes 198
 - hemophilia 427
 - plasma 213–214
 - platelets 396–397
- prostate cancer, I blood group 93
- protamine 449
- protein blood groups
 - ABCC1 system 117
 - AUG system 117
 - Cartwright system 115
 - Chido/Rogers system 115
 - Colton system 114–115
 - CTL2 system 117
 - Diego system 114
 - Dombrock system 115–116
 - Duffy system 112–113
 - Gerbich system 115
 - GIL system 114–115
 - Indian system 115
 - JR system 116
 - Kell 111–112
 - Kidd system 113–114
 - Knops system 115
 - LAN system 116
 - LW system 107
 - MAM system 117
 - MNS system 109–111
 - OK system 116
 - overview 110
 - PEL system 116–117
 - RAPH system 116
 - Rh system 100–107
 - Scianna system 114
 - VEL system 117
 - Xg system 114

- prothrombin complex concentrates (PCC)
214, 303, 443–444
adverse reactions 444
burn patients 480
dosing 444
indications 443–444
issuance 308
manufacturing 443
obstetrics 377
purification 231–232
storage 443
surgical protocols 460
trauma patients 480
- prothrombin deficiency 437
- prothrombin (FII) 201, 437
- prothrombin time (PT) 205–208, 457–458
- protocols
obstetric hemorrhage 376–377
red blood cell administration 339–341
- protoplatelets 160
- protozoan diseases
red cell exchange 281–282
see also babesiosis; Chagas disease;
leishmaniasis; malaria; malaria,
babesiosis; microfilariasis;
toxoplasmosis
- PRP *see* platelet-rich plasma
- PSOs *see* patient safety organizations
- PTP *see* posttransfusion purpura
- Public Health Service Act (PHSA) 66
- pulmonary arterial hypertension (PAH),
sickle cell disease 334–335
- pulmonary endothelial cells, transfusion-
related acute lung injury 574
- purification
immunoglobulin G 238–240
immunoglobulins 224–227, 238–240
plasma proteins 216–235
activated prothrombin complex
concentrate 227–228
albumin 222–224
 α_1 -proteinase inhibitor 228
antithrombin III 230
C1 inhibitor 229–230
factor IX 232
factor VIII 233–234
factor X 227
factor XI 228–229
factor XIII 227
fibrinogen 231
immunoglobulins 224–227, 238–240
pathogen reduction 219–221
prion safety 222
prothrombin complex concentrate
231–232
validation of virus reduction/removal
219–220
virus filtration 221
virus inactivation 220–221
virus reduction 219–220
von Willebrand factor 232–233
- red blood cells 151–152
see also manufacturing
- pVHL *see* von Hippel–Landau protein
- pyruvate kinase activators 596
- pyruvate kinase deficiency (PKD) 338
- QALY *see* quality-adjusted life years
- QC *see* quality control
- quality control (QC)
hospital transfusion services 71
human tissue allografts 679–680
- quality evaluation, red blood cells
156–157
- quality-adjusted life years (QALY),
autologous donations 29
- RA *see* rheumatoid arthritis
- Rac family small GTPases (RAC1 and
RAC2) 160
- radiological agent attacks 16
- RAPH blood group system 116
- rapid infusion practices 313–314, 376–377
complications 561–564
- Rapoport–Luebering shunt (2,3-DPG
shunt) 145–146, 147
- Ras homolog family member A
(RhoA) 160
- RBCs *see* red blood cells
- RCE *see* red cell exchange
- real-time polymerase chain reaction
(real-time PCR), human leukocyte
antigens 628
- rebound thrombocytopenic 614
- recalls, human tissue allografts 682–683
- recipient-specific blood donation 29
- recipients
ABO typing 124
administration 129
medications, apheresis 265–266
monitoring 312
notification of discovery of a donor
disease 42
patient blood management 293–305
platelet alloimmunization 171–174
pretransfusion testing 123–130
Rh typing 124–125
skin disinfection 535
- recombinant activated factor VII (rFVIIa)
304, 445–446
adverse reactions 445–446
burn patients 480
dosing 445–446
indications 445–446
manufacturing 445–446
oncology patients 486
storage 445–446
trauma patients 480
- recombinant clotting factors, storage 308
- recombinant factor IX (rFIX) 431–432
- recombinant factor VIII (rFVIII) 427,
436–437
- recombinant factor Xa (andexanet alfa)
449–450
- recombinant products, European
regulation 77
- records management, disasters 18
- recovery, disaster management 15
- recruitment
blood donation 27–29
disasters 28–29
recipient-specific 29
retention 28
theories of behavior 28
- red blood cell antibodies, hemolytic disease
of the fetus and newborn 365
- red blood cells (RBCs) 133–157
ABO typing 37–38, 38
additive solutions 152–154
adenosine triphosphate 143, 145,
147–148
- administration
acute myocardial infarction
321–322
cardiac surgery 319–321
children 322, 383–385
chronic anemia 324
clinical trials 318–322
cold agglutinin disease 354
complications 342–345
critical care 319
decision-making 323
dosing 324
fetal 379
guidelines 322–324
hemolytic disease of the fetus and
newborn 370–371
infants 382–383
maternal 378
microcirculatory effects 316–317
monitoring 341–342
oncology patients 322, 482–484
orthopedic surgery 321
paroxysmal cold hemoglobinuria 355
paroxysmal nocturnal
hemoglobinuria 362–363
perioperative guidelines 464–466
preterm infants 382–383
protocols 339–341
sickle cell disease 331–335, 332
surgical outcomes 455–457
targets 341–342
thalassemia 335–337
transfusion threshold 324
upper gastrointestinal bleeding 321
warm autoimmune hemolytic
anemia 350–351
- alloimmunization 342–343, 483
- alternate metabolic substrates 146–147
- anemia of chronic inflammation 141
- antibody detection 38
- anticoagulant-nutrient solutions 152
- antigen–antibody interactions 120–121

- apheresis requirements 256
- bacterial contamination 540–541
- biochemistry 143–150, 144
- biosynthesis 135, 148–149
- blood groups *see* blood groups
- DNA-based group typing 127–128, 129
- dosing 324
- 2,3-DPG shunt 145–146, 147
- effectiveness 155–156
- enzymopathies 328–329, 337–338
- eryptosis 150
- erythropoiesis 133–142
- erythropoietic therapies 141–142
- expiration time 307
- frozen storage 156
- G proteins 148
- glucose metabolism 145–148
- guanine nucleotides 148
- irradiation 155, 483
- issuance 307
- leukocyte reduction 155, 483
- macrocytic anemia 138–140
- membrane metabolism 149–150
- membrane mutations 329, 338–339
- metabolic regulation 147–148
- metabolism 143–150
- microcirculatory effects of
 - administration 316–317
- microcytic anemia 140–141
- pathogen reduction 155, 498
- pentose shunt 146, 147
- preservation 144, 150–157, 307
 - additive solutions 152–154
 - anticoagulant-nutrient solutions 152
 - effectiveness 155–156
 - frozen storage 156
 - leukocyte reduction 155
 - pathogen reduction 155
 - pH 153
 - principles 150–151
 - rejuvenation 156
 - storage containers 154–155
 - temperature and time lapse 154
 - washing 155
- pretransfusion testing 339–340
- production kinetics 138
- quality evaluation 156–157
- rejuvenation 156
- Rh proteins function 105
- Rh typing 37–38, 105–109, 124–128
- salvage devices 312
- separation 33, 151–152
- simple transfusion 340–341
- storage 307
- storage containers 154–155
- structural hemoglobin mutations 47, 327–328
- thalassemia 141, 335–337
- transfusion threshold 324
- in vivo recovery 156–157
- volume reduction 310
- washing 155, 300–301
 - see also* alpha thalassemia; beta thalassemia; sickle cell disease; thalassemia
- red cell exchange (RCE) 278–282
 - acute chest syndrome 279, 333
 - acute multiorgan failure syndrome 279–280
 - acute vaso-occlusive stroke 279
 - aplastic crisis 333–334
 - babesiosis 282
 - chronic transfusion therapy 280–281
 - contraindications 335
 - fraction of the preprocedure cells remaining 278–279
 - iron overload prevention 281
 - malaria 282
 - ophthalmological complications of SCD 335
 - pregnancy 281, 334
 - preoperative 281, 334
 - protocol 341
 - protozoan diseases 281–282
 - pulmonary arterial hypertension 334–335
 - sickle cell disease 279–281
 - sickle hepatopathy 334
 - stroke prevention 280–281, 332–333
- refractoriness, platelets 174, 398–399, 422, 485
- Refsum's disease, apheresis 269
- regulation
 - adverse transfusion reaction reporting 70–73
 - blood collection establishments 66–70
 - defective products reporting 69, 72
 - devices 70
 - disaster management 17–18
 - erythropoietin production 136–137
 - health emergencies 17–18, 21–23
 - hematopoietic stem cells 623
 - hospital transfusion services 70–73
 - inspections 69
 - megakaryopoiesis 162–165
 - prion safety 531
 - red blood cell metabolism 147–148
 - screening 39–40, 41–42
 - source plasma collection 34
 - United states history 65–66
 - World Health Organization 74–75
- regulatory T cells 634
- reimbursement, human tissue allografts 683
- rejection
 - cardiac allografts, extracorporeal photopheresis 287–288
 - lung allografts, extracorporeal photopheresis 288
- rejuvenation, red blood cells 156
- release, blood components 307
- relevant transfusion-transmitted infections (RTTIs)
 - autologous donations 29
 - donor screening 29–32, 34–36
 - see also* transfusion-transmitted infections
- renal tissue engineering 654–656
- repeat donors 28
- repeat reactive (RR) samples, HIV 43
- replacement solutions, therapeutic plasma exchange 261–263, 265
- reportable deviations, blood collection establishments 69
- reporting
 - adverse transfusion reactions 70–73, 129–130
 - defective products 69, 72
 - transfusion service errors 71–72
 - transfusion-related deaths 71
- reproductive system tissue engineering 650–651
- resource-limited contexts, infectious disease testing 40–41
- respiratory capacity, stored platelets 183
- respiratory infections, ABO system 87
- responses, disaster management 15
- restless legs syndrome (RLS), donation-related iron deficiency 60
- Retacrit *see* epoetin alfa-epbx
- retention, donors 28
- reticulated platelets (RPs) 160–161, 166–167
- reticulin fibrosis 614
- reticulocyte suppression/destruction 547
- retroviruses 515–517
 - see also* human immunodeficiency virus; human T-cell lymphotropic virus
- returns, blood components 309
- Revolade *see* eltrombopag
- rFIX *see* recombinant factor IX
- rFVIIa *see* recombinant activated factor VII
- rFVIII *see* recombinant factor VIII
- Rh immune globulin 408
- Rh system 100–107
 - altered CE 103–104
 - antibodies 106, 107
 - biological roles 105
 - C/c & E/e antigens 102–103
 - D antigen 101
 - discovery 8
 - donor testing 37–38
 - expression 101–104
 - fetal typing 105
 - genetics 101–106
 - genotyping 105–106
 - hemolytic disease of the fetus and newborn 106
 - history 100
 - homology 105
 - homozygosity 105, 106

- Rh system (*cont'd*)
 immune responses 106–107
 membrane complex 104–105
 nomenclature 100, **101**
 partial D 102, 105–106
 RhAG association 101
 serology 100–104, 106–107
 silenced CE 103
 transfusions 106–107
 weak D 101–102, 103, 105–106
- Rh typing 37–38
 fetal 105
 genotyping 105–109
 hemolytic disease of the fetus and newborn 365–366
 recipients 124–125
- Rh-associated glycoprotein (RhAG) 101
- RhAG *see* Rh-associated glycoprotein
- RHCE 101
- RHD 101, 105
- rheumatoid arthritis (RA),
 neutropenia 192
- RhoA *see* Ras homolog family member A
- riboflavin/UV pathogen reduction 492,
 495, 497, 498, 499
- RIF 117
- risk, definition 503
- risk factors
 anemia 317–319
 donation-related iron depletion 56–58
 gene therapy 643–644
 infections, ABO system 86–87
 oncology patients 487
 paroxysmal nocturnal
 hemoglobinuria 358
 post-donation acute adverse reactions
 51, 53
 Rh antibodies 106
- rituximab
 cold agglutinin disease 353
 immune thrombocytopenic
 purpura 409
 neutropenia 192
 warm autoimmune hemolytic
 anemia 350
- RNA testing, HIV 43
- Robert T. Stafford Disaster Relief and
 Emergency Assistance Act
 (1988) 15
- Romiplostim (Nplate) 611–613
- RP *see* reticulated platelets
- RR *see* repeat reactive
- RTTIs *see* relevant transfusion-transmitted
 infections
- S/D *see* solvent and detergent
- SABM *see* Society for the Advancement of
 Blood Management
- safety measures, human tissue allografts
 679–680
- SAG-M *see* saline, adenine, and glucose
 with mannitol
- saline, adenine, and glucose with mannitol
 (SAG-M) solution 151, 152–153
- saline, adenine, and glucose (SAG)
 solution 151
- saline solutions
 innovation 7
 source plasma donors 35
- salvage devices 312
- sample collection, pretransfusion
 testing 123–124
- SAO *see* Southeast Asian Ovalocytosis
- sargramostim (Leukine) 608
- SARS-COV-1, ABO type 87
- SARS-COV-2 14, 16, 18–23
 ABO type 87
 convalescent plasma 23
 vaccine-induced immune thrombotic
 thrombocytopenia 417
- SBDS *see* Shwachman–Bodin–Diamond
 syndrome
- scaffolds
 gastrointestinal tissue 653–654
 lung tissue 648–649
 peripheral nerve system tissue 651
 renal tissue 654–655
 reproductive system tissue 650
 skeletal muscle 652–653
- SCD *see* sickle cell disease
- scheduling, immunoglobulin therapy
 244–247
- SCI *see* silent cerebral infarcts
- Scianna blood group system 114
- SCID *see* severe combined
 immunodeficiency
- SCIG *see* subcutaneous IgG
- SCN1 191
- SCNs *see* severe congenital neutropenias
- screening 29–32, 37–48
 ABO antibody titers 38–39
 ABO system 37–39, **38**
 administration 31–32
 automated systems **40**
 babesiosis 45, 524
 bacterial infections 535
 biovigilance 129–130
 blood derivatives 46
 Chagas' disease 46
 Chagas disease 46, 525
 CJD/vCJD risk 31
 coagulation tests 204–208, 457–458
 compatibility testing 122–130
 cytomegalovirus 46, 519
 dengue virus 517
 direct antiglobulin testing 39
 donated blood 39, **40**
 Donor History Questionnaire 30–31
 donor management 41–42, **41**
 donor reentry **41**, 42–43
- donor–recipient mismatches 128–129
- educational materials 31
- extended blood group antigen typing 47
- false positives 39
- ferritin levels 61–62, 63
- granulocyte donors 194–195
- hemoglobin S 47
- hepatitis A 47, 507–508
- hepatitis B 43–44, 510–511
- hepatitis C 44, 511
- hepatitis D 514
- herpesviruses 519
- HIV 43, 516
- HTLV 517
- human leukocyte antigen 47
- human T-cell lymphotropic virus 44
- IgA deficiency 47
- IgG depletion 63
- infectious diseases 37, 39–47
- informed consent 31–32
- leishmaniasis 528
- limiting blood loss 304
- lookback 42
- malaria 526
- men who have sex with men 31
- pandemic influenza 521
- Parvovirus B19 47, 520
- platelet antigen typing 47
- platelets 46
 pooling 39, 43
- product management 42
- RBC antigens 38
- recipient notification 42
- regulations 39–40, 41–42
- resource-limited settings 40
- Rh groups 37–38
- Rh system 37–38
- sequence 40
- source plasma donors 34–35
 ABO antibody titers 38–39
 direct antiglobulin testing 39
 infectious diseases 40–41
 RBC antigens 38
- syphilis 45–46
- TT virus 521
- United States regulations 37, **38**, 39–40,
 41–42
- vital sign measurement 32
- West Nile virus 45, 518
- World Health Organization
 requirements 39
- Zika virus 45
see also pretransfusion testing; testing
- Sd^a antigen (SID) 97–99
 biochemistry 97
 biological roles 98–99
 expression 97–98
 molecular biology 97–98
 serology 97
 synthesis 97

- transfusion 97
- xenotransplantation 98–99
- Se *see* secretor-positive
- secondary culture 536–537
- secondary erythrocytosis, apheresis 283–284
- secondary immune deficiencies (SID), immunoglobulins 245
- secondary immune responses 119
- secondary stroke prevention, red cell exchange 280–281, 333
- secretor gene (*FUT2*) 81, 82, 89
- secretor-positive (Se) individuals, ABO system 81–82
- separation
 - blood components 33
 - activated prothrombin complex concentrate 227–228
 - albumin 222–224
 - alpha₁-proteinase inhibitor 228
 - antithrombin III 230
 - C1 inhibitor 229–230
 - factor IX 232
 - factor VIII 233–234
 - factor X 227
 - factor XI 228–229
 - factor XIII 227
 - fibrinogen 231
 - immunoglobulins 224–227, 238–240
 - pathogen reduction 219–221
 - prion safety 222
 - prothrombin complex concentrate 231–232
 - red blood cells 151–152
 - validation of virus reduction/removal 219–220
 - virus filtration 221
 - virus inactivation 220–221
 - virus reduction 219–220
 - von Willebrand factor 232–233
 - see also* purification
- sepsis, neutropenia 192
- septic phlebitis, blood donation 52
- sequence-specific oligonucleotide probe hybridization (SSOP) 628
- sequence-specific primer polymerase chain reaction (SSP) 628
- sequestration, platelets 167, 392–393
- serological assays, human leukocyte antigens 630
- serology
 - ABO system 82
 - I blood group 90–91
 - Lewis blood group 87
 - P blood group system 94–95
 - Rh system 100–104, 106–107
 - Sd^a antigen 97
- serum albumin in saline, therapeutic plasma exchange 261–262
- seventeenth century
 - animal transfusions 4
 - animal-to-human transfusions 4–5
 - discovery of circulation 3
- severe combined immunodeficiency (SCID), gene therapy 644
- severe congenital neutropenias (SCNs) 191–192
- shigatoxins (Stx) 97
- Shigella dysenteriae*, P blood group 97
- Shwachman–Bodin–Diamond syndrome (SBDS) 191
- sickle cell disease (SCD) 330–335
 - acute chest syndrome 279, 333
 - acute multiorgan failure syndrome 279–280
 - acute splenic sequestration crisis 334
 - acute stroke 332
 - aplastic crisis 333–334
 - ASPEN 280
 - chronic transfusion therapy 280–281
 - contraindications 335
 - delayed hemolytic transfusion reactions 343–344
 - hemoglobin S testing 47
 - indications for transfusion 331–335, 332
 - LW system 107
 - ophthalmological complications 335
 - pathophysiology 330–331
 - pregnancy 334
 - preoperative red cell exchange 281, 334
 - primary stroke prevention 332–333
 - pulmonary hypertension 334–335
 - red cell exchange 279–281
 - Rh system proteins 106
 - secondary stroke prevention 333
 - sickle hepatopathy 334
 - silent cerebral infarcts 280
 - stroke prevention 280–281, 332–333
 - symptomatic anemia 333–334
- SID *see* Sd^a antigen; secondary immune deficiencies
- silenced CE phenotype 103
- silent cerebral infarcts (SCI), prevention 280
- simple transfusion
 - hemolytic disease of the fetus and newborn 371
 - red blood cells 340–341
- skeletal muscle tissue engineering 652–653
- skin allografts 675
- skin disinfection 535
- skin tissue engineering 658
- SLE *see* systemic lupus erythematosus
- Society for the Advancement of Blood Management (SABM) 293, 294
- software, blood establishments 70
- solid organ transplantation, ABO system 85
- solid-phase adherence assays 125
- solid-phase testing, human leukocyte antigens 630
- soluble transferrin receptor, iron-deficient erythropoiesis 57
- solvent and detergent (S/D)
 - pathogen reduction 493, 496, 500
 - plasma treatment 33, 220–221
 - plasma usage 302–303
- somatic hypermutation 120
- sore arms, blood donation 52
- source plasma (SP)
 - ABO antibody titers 38–39
 - collection 34–36
 - chronic effects 63–64
 - direct antiglobulin testing 39
 - donor screening 34–35
 - infectious disease testing 34–36, 40–41
 - RBC antigens 38
- Southeast Asian Ovalocytosis (SAO) 339
- SP *see* source plasma
- Spanish Civil War 9
- specialized therapeutic plasma processing 275–276
- Spectra Optia instrument 254
- splenectomy
 - immune thrombocytopenic purpura 408–409
 - warm autoimmune hemolytic anemia 350
- Splenomegaly 192–193
- sponge rinsing 301
- SSOP *see* sequence-specific oligonucleotide probe hybridization
- SSP *see* sequence-specific primer polymerase chain reaction
- Stafford Act (1988) 15
- stem cell transplantation
 - ABO system 85–86
 - myeloid growth factors 610
- steroid responsive encephalopathy associated with autoimmune thyroiditis (Hashimoto's encephalopathy) 269
- stimulation, granulocyte production 195
- storage
 - activated prothrombin complex concentrate 444
 - andexanet alfa 450
 - antifibrinolytics 447
 - cell-based immunotherapies 308
 - cryoprecipitate 308
 - desmopressin 448
 - equipment 308–309
 - granulocytes 195, 308, 487
 - hematopoietic stem cells 308, 620–621
 - plasma 308
 - plasma composition effects 203

- storage (*cont'd*)
- platelets 181–187, 307
 - additive solutions 184–185
 - containers 183
 - cryopreservation 186
 - lesions 183–184
 - lyophilization 186–187
 - metabolic needs 181–183
 - pH 182–183
 - respiratory capacity 183
 - temperature 181–182, 186
 - protamine 449
 - prothrombin complex concentrates 443
 - recombinant activated factor VII 445
 - recombinant clotting factors 308
 - red blood cells 150–157, 307
 - additive solutions 152–154
 - anticoagulant-nutrient solutions 152
 - effectiveness 155–156
 - frozen storage 156
 - leukocyte reduction 155
 - pathogen reduction 155
 - pH 153
 - principles 150–151
 - rejuvenation 156
 - storage containers 154–155
 - temperature and time lapse 154
 - washing 155
 - vitamin K 446
- storage containers
- platelets 183
 - red blood cells 154–155
- storage-generated cytokines 555
- streptococcal infections, PANDAS 269
- Streptococcus suis*, P blood group 97
- structural hemoglobin mutations 47, 327–328
- structure, ABO antigens 81–84
- Stx *see* shigatoxins
- subcapsular cataracts, leukapheresis risk 54–55
- subcutaneous IgG (SCIG) therapy 240–243
- sulfur metabolism, red blood cells 148–149
- superinfection, hepatitis D 513
- surgical outcomes
- anemia 454
 - red blood cell administration 455–457
- surgical patients
- activated clotting time 459
 - acute nonvolemia hemodilution 462
 - anemia 453–455
 - anticoagulants 459–460
 - antiplatelet therapies 460–461
 - blood avoidance techniques 461–462
 - conservative practice 461
 - direct oral anticoagulants 460
 - guidelines 464–466
 - plasma administration 464–470
 - platelet administration 466, 469–470
 - point-of-care viscoelastic assays 459
 - preoperative hemostatic testing 457–459
 - red blood cell administration 455–457, 464
 - topical hemostatic therapies 462–463
 - see also* perioperative practice; preoperative. . .
 - syncopal reactions, blood donation 51–52
 - syphilis
 - testing 45–46
 - transfusion-transmitted 541
 - systemic lupus erythematosus (SLE)
 - apheresis 273
 - neutropenia 192
 - pregnancy 375
- T-cell immunotherapies
- cancer 633, 636–637
 - chimeric antigen receptor-expressing 634, 635–637
 - donor lymphocytes 633–634
 - engineered 634–637
 - nonengineered 633–634
 - regulatory 634
 - tumor-infiltrating lymphocytes 634
 - viral infections 637–638
- T-cell independent response 119
- T-cells, chimeric antigen receptor therapy 488
- TA-GVHD *see* transfusion-associated graft-versus-host disease
- TACO *see* transfusion-related circulatory overload
- TAD *see* transfusion-associated dyspnea
- TAFI *see* thrombin-activatable fibrinolysis inhibitor
- TALENs *see* transcription activator-like effector nucleases
- Tamm-Horsfall protein (uromodulin) 97
- targets, red blood cell administration 341–342
- TBO-filgrastim (Granix) 608
- temperature, red blood cell storage 154
- tendon allografts 674–675
- terminal platelet production 160–161
- test tube methods, Rh typing 124–125
- testing
- biovigilance 129–130
 - coagulation 204–208, 457–458
 - compatibility 122–130
 - donated blood 37–48
 - ABO antibody titers 38–39
 - ABO system 37–39, **38**
 - automated systems **40**
 - babesiosis 45
 - blood derivatives 46
 - Chagas' disease 46
 - cytomegalovirus 46
 - direct antiglobulin testing 39
 - donated blood 39, **40**
 - donor communication 41–42, **41**
 - donor reentry **41**, 42–43
 - extended blood group antigen typing 47
 - false positives 39
 - hemoglobin S 47
 - hepatitis A 47
 - hepatitis B 43–44
 - hepatitis C 44
 - HIV 43
 - human leukocyte antigen 47
 - human T-cell lymphotropic virus 44
 - IgA deficiency 47
 - infectious diseases 37, 39–47
 - lookback 42
 - Parvovirus B19 47
 - platelet antigen typing 47
 - platelets 46
 - pooling 39, 43
 - product management 42
 - RBC antibody detection 38
 - RBC antigens 38
 - recipient notification 42
 - regulations 39–40, 41–42
 - resource-limited contexts 40–41
 - resource-limited settings 40
 - Rh groups 37–38
 - Rh system 37–38
 - sequence 40
 - syphilis 45–46
 - United States regulations 37, **38**, 39–40, 41–42
 - West Nile virus 45
 - World Health Organization requirements 39
 - Zika virus 45
- donor–recipient mismatches 128–129
- ferritin levels 61–62, 63
- granulocyte collection 194–195
- IgG depletion 63
- limiting blood loss 304
- neonates, HDFN 368
- source plasma donors 34–36
 - ABO antibody titers 38–39
 - direct antiglobulin testing 39
 - infectious diseases 40–41
 - RBC antibody detection 38
- United States regulations 37, **38**, 39–40, 41–42
- World Health Organization requirements 39
- see also* pretransfusion testing
- thalassemia 141, 328, 335–337
- gene editing 645
- thawing
 - hematopoietic stem cells 621–622
 - plasma 311
- The Joint Commission (TJC) 17, 72–73
- theory of planned behavior (TPB) 28

- therapeutic phlebotomy 278, 282–285
 hereditary hemochromatosis 284–285
 polycythemia vera 283
 secondary erythrocytosis 283–284
- therapeutic plasma exchange (TPE) 214, 259–277
 5% serum albumin in saline 261–262
 acute disseminated
 encephalomyelitis 268
 ANCA-associated vasculitis 272
 angiotensin-converting enzyme inhibitors 265
 antibody-mediated rejection 274
 anticoagulation 251–252
 autoantibody hemolytic anemia 271
 biochemical changes 263–264
 catastrophic antiphospholipid syndrome 271
 children 266
 chronic inflammatory demyelinating polyradiculoneuropathy 267
 citrate toxicity 266
 cold agglutinin disease 353–354
 complement-mediated thrombotic microangiopathy 270
 complications 264–266
 continuous renal replacement therapy 263
 controversial applications 274–275
 cryoglobulinemia 271–272
 cryoprecipitate 262–263
 desensitization in transplant recipients 274
 dilated cardiomyopathy 275–276
 exchange volumes 260–261
 extracorporeal membrane oxygenation 263
 familial hypercholesteremia 276
 focal segmental glomerulosclerosis 272–273
 fresh frozen plasma 262–263
 Goodpasture syndrome 272
 Guillain-Barré syndrome 261, 266–267
 Hashimoto's encephalopathy 269
 hematologic disorders 269–272
 hemolytic disease of the fetus and newborn 370–371
 hydroxyethyl starch 263
 hypergammaglobulinemia 270–271
 immunoadsorption 275–276
 instrumentation 259–260
 Lambert-Eaton myasthenic syndrome 268
 LDL removal 276
 N-methyl-D-aspartate receptor antibody encephalitis 267
 multiple sclerosis 268
 mushroom poisoning 273
 myasthenia gravis 267
 myeloma cast nephropathy 273
 neurological disorders 266–269
 neuromyelitis optica spectrum disorder 268–269
 overdose 273
 PANDAS 269
 paraproteinemic demyelinating polyneuropathies 268
 phytanic acid storage disease 269
 rejection of transplants 274
 replacement solutions 261–263, 265
 specialized 275–276
 systemic lupus erythematosus 273
 techniques 259–263
 thrombotic microangiopathies 269–271
 thrombotic thrombocytopenic purpura 261, 270
 thyroid storm 273
 ticlopidine-associated thrombotic microangiopathy 270
 transplantation 273–274
 vascular access 260, 265
 vasculitis 272
 vasculitis with hepatitis B-associated polyarteritis nodosa 272
 voltage-gated potassium channel antibody diseases 269
 Wilson Disease 273
see also plasmapheresis
- therapeutic platelet transfusions 398–400
 therapeutic thrombocytapheresis 286
 therapeutics, health emergencies 23
 Therasorb 275
 thoracentesis
 plasma administration 468
 platelet administration 469
 thrombin 201, 203
 thrombin time (TT) 205–208
 thrombin-activatable fibrinolysis inhibitor (TAFI) 203
 thrombocytapheresis 286
 thrombocytopenia
 alloantigens **418**
 alloimmune 417–422
 cancer 394
 chemotherapy-induced 615
 dialysis 394
 dosing 397
 drug-induced immune 411–417, **412**
 heparin-induced 394, 413–417
 impaired platelet production 392
 laboratory tests 402–406
 microangiopathic hemolytic anemias 393–394
 other medications causing 394–395
 passive alloimmune 421–422
 platelet refractoriness 398–399, 422
 platelet substitutes 400
 platelet transfusion 395–400
 platelet transfusions 395–400
 posttransfusion purpura 395, 421
 preoperative transfusions 397–398
 therapeutic transfusions 398–400
 thrombopoietic growth factors 611–616
 thrombopoietin receptor agonists 401
 uremia 394
 vaccine-induced 417
see also individual thrombocytopenic disorders. . .
- thrombocytosis, apheresis 285–286
 thromboembolic events (TEEs), immunoglobulin therapy 242
 thrombolytic agents, paroxysmal nocturnal hemoglobinuria 360
 thrombopoietic growth factors 611–616
 adverse effects 613–614
 indications 614–615
 receptor agonists 611–613, 615–616
 thrombopoietin receptor agonists (TPO-RAs) 401, 409, 611–613, 615–616
 thrombopoietin (TPO) 158–160, 162–166, 611
 oncology patients 486
 thrombosis
 erythroid growth factors 605
 thrombopoietic growth factors 613
 thrombosomes, oncology patients 486
 thrombotic microangiopathic anemias (TMAAs) 373–374
 thrombotic microangiopathies (TMAs)
 apheresis 269–271
 drug-induced 413
 platelet maturation pathologies 160–162
 thrombotic thrombocytopenic purpura (TTP)
 apheresis 261, 263, 270
 pregnancy 374–375
 thyroid storm, apheresis 273
 thyroiditis, apheresis 269
 ticlopidine-associated thrombotic microangiopathy 192, 270
 time lapse, red blood cell separation 154
 tissue engineering 648–659
 bone 656
 cardiac 657
 cartilage 657–658
 COVID-19 650
 gastrointestinal 653–654
 lung 648–650
 peripheral nerve system tissue 651–652
 renal 654–656
 reproductive system 650–651
 skeletal muscle 652–653
 skin 658
 urological 658–659
 vascular 656–657
 tissue hypoxia, erythropoietin regulation 136–137
 tissue processing, human tissue allografts 680
 tissue-specific regulation, ABO system 84
 TJC *see* The Joint Commission
 TMA *see* transcription-mediated amplification

- TMAAs *see* thrombotic microangiopathic anemias
- TMAAs *see* thrombotic microangiopathies
- toxoplasmosis 528
- TP *see* *Treponema pallidum*
- TPB *see* theory of planned behavior
- TPE *see* therapeutic plasma exchange
- TPO *see* thrombopoietin
- TPO-RAs *see* thrombopoietin receptor agonists
- tranexamic acid (TXA) 377, 447–448
adverse reactions 448
burn patients 479–480
dosing 448
indications 447–448
manufacturing 447
storage 447
surgical patients 462
trauma patients 479–480
- transamination, red blood cells 148
- transbronchial lung biopsy
plasma administration 468
platelet administration 469
- transcription activator-like effector nucleases (TALENs) 644
- transcription factors, erythroid differentiation 133–135
- transcription-mediated amplification (TMA) testing 39
- transferrin receptor (CD17) 134
- transfusion protocols, red blood cells 339–341
- transfusion safety officers (TSOs) 129
- transfusion services
accreditation 73
adverse reaction reporting 70–73
defective product reporting 72
operational chain 11
pretransfusion testing 122–130
sample collection 123–124
transfusion-related death reporting 71
United States regulations 70–73
World Health Organization programs 74–75
- transfusion thresholds, red blood cells 324
- transfusion-associated dyspnea (TAD) 580
- transfusion-associated graft-versus-host disease (TA-GVHD) 582–586
component irradiation 309–310
diagnosis 584–585
immunocompromised patients 584
immunodeficiency syndromes 583–584
incidence 583
oncology patients 483
pathogen reduction 499
pathophysiology 582
prevention 252–256
treatment 586
- transfusion-related acute lung injury (TRALI) 10, 569–579
antibodies 571, 574–576, 578
biologically active lipids 576
blood donation 33
CD40 ligand 576
children 573
clinical features 569–570
critically ill patients 577
diagnosis 571–572
donor investigation and management 577–578
human leukocyte antigens 575–576
human neutrophil antigens 574–575
immunoglobulins 576
incidence 572–573
inverse 576, 579
monocytes 574
multiple hit/threshold theory 576–577
neonates 573
neutrophils 573–574
nonantibody 576, 579
pathophysiology 570–571, 573–577
plasma 215
platelets 574
pooled plasma 578–579
prevention 578–579
pulmonary endothelial cells 574
therapeutic plasma exchange 265
treatment 573
- transfusion-related circulatory overload (TACO) 563–564, 579–580
diagnosis 580
incidence 580
plasma 215
prevention 580
treatment 580
volume reduction 310
- transfusion-related deaths, reporting 71
- transfusion-transmitted infections (TTIs) 507–542
1900s 9–11
automated testing systems 40
babesiosis 45, 523–524
bacterial contamination 533–542
Chagas disease 46, 524–525
chikungunya virus 518
cytomegalovirus 519
dengue virus 517–518
donor screening 34–36
ebola virus 520–521
Epstein–Barr virus 519
hepatitis A 507–508
hepatitis B 508–511
hepatitis C 511–513
hepatitis D 513–514
hepatitis E 514
hepatitis F 515
herpesviruses 519
HIV 10, 31, 43, 96, 192, 515–516
HTLV 44, 516–517
introduction of precautions 10–11
leishmaniasis 527–528
lymphatic choriomeningitis 521
malaria 524–525
microfilariasis 528–529
pandemic influenza 521
parasites 523–529
Parvovirus B19 519–520
prions 529–531
screening 37, 39–47
general concepts 39–40
resource-limited contexts 40–41
see also individual infectious agents. . .
prerelease testing; testing
syphilis 541
toxoplasmosis 528
TT virus 521
viral 507–522
West Nile virus 518
- transfusion-transmitted viral infections (TTVIs) *see* transfusion-transmitted infections
- transfusional iron burden 589–592
- transfusional iron overload *see* iron overload
- transfusions *see* administration; blood administration
- Transfusions Medicine Committee 73
- transmissible spongiform encephalopathies (TSEs) 11, 31, 222, 529–531
- transmission, hepatitis B 509–510
- transplantation
ABO system 85–86
adverse event monitoring 682
alloimmune thrombocytopenia 422
desensitization 274
donation tracking 678–679
extraembryonic tissue 677
hospital-based tissue services 679
human leukocyte antigens 630–632
human tissue allografts 670–683
immunoglobulin therapy 247
Lewis blood group 89
oversight 677–678
recalls and lookback 682–683
reimbursement 683
rejection 274
Sd^a antigen 98
surveillance 680–682
therapeutic plasma exchange 273–274
tissue engineering 648–659
- transplantation-associated alloimmune thrombocytopenia 422
- transport, blood components 309
- trastuzumab emtansine 160
- trauma patients 471–481
burns 478–481
coagulation factor replacement 480
coagulopathies 474–475

- cryoprecipitate 480
- damage-control resuscitation 475–478
- freeze-dried plasma 480
- prothrombin complex concentrates 480
- recombinant activated factor VII 480
- tranexamic acid 479–480
- whole blood 480
- treatment
 - allergic responses 559
 - anaphylaxis 560–561
 - cold agglutinin disease 353–354
 - combined factor V and factor VIII deficiency 438
 - drug-induced immune hemolytic anemia 357–358
 - dysfibrinogenemia 441–442
 - factor V deficiency 438
 - factor VII deficiency 438–439
 - factor X deficiency 439
 - factor XI deficiency 440
 - factor XIII deficiency 440–441
 - febrile nonhemolytic reactions 556–557
 - hemolytic transfusion reactions 550
 - hemophilia 426–434
 - heparin-induced thrombocytopenia 414–417
 - hepatitis B 511
 - hepatitis C 511–513
 - HIV 516
 - hypodysfibrinogenemia 441–442
 - immune thrombocytopenic purpura 407–411
 - iron overload 592–596
 - paroxysmal cold hemoglobinuria 354–355
 - paroxysmal nocturnal hemoglobinuria 360–363
 - posttransfusion purpura 421
 - prothrombin deficiency 437
 - transfusion-associated graft-versus-host disease 586
 - transfusion-related acute lung injury 573
 - transfusion-related circulatory overload 580
 - von Willebrand disease 436–437
 - warm autoimmune hemolytic anemia 349–351
 - see also* administration
- Treponema pallidum* (TP) 45–46, 541
- Trima Accel instrument 254
- Trypanosoma cruzi* (Chagas' disease) 46
- TSEs *see* transmissible spongiform encephalopathies
- TSOs *see* transfusion safety officers
- TT *see* thrombin time
- TT virus (TTV) 521
- TTP *see* thrombotic thrombocytopenic purpura
- TTVIs (transfusion-transmitted viral infections) *see* transfusion-transmitted infections
- tumor-infiltrating lymphocytes 634
- twentieth century 7–11
 - anticoagulants development 8–9
 - blood bank development 9
 - blood groups discovery 7–8
 - compatibility testing 8
 - component therapy development 9
 - direct transfusions 7–8
 - discovery of hepatitis viruses 9–10
 - HIV/AIDS epidemic 10
 - transfusion-related acute lung injury 10
 - transfusion-transmitted infections 9–11
 - variant Creutzfeld–Jakob disease 11
- TXA *see* tranexamic acid
- UCB *see* umbilical cord blood
- Udenyca *see* pegfilgrastim-cbqv
- ultraviolet A (UV-A), with amotosalen 490, 492, 495, 497, 498, 499
- ultraviolet C (UV-C) 493, 496, 497, 500
- ultraviolet (UV) treatment
 - with amotosalen 490, 492, 495, 497, 498, 499
 - plasma 221, 495–496, 497
 - with riboflavin 492, 495, 497, 498, 499
- umbilical cord blood (UCB) 621
- unexpected antibodies
 - donor–recipient testing 128
 - Rh typing 124
- unit labeling 129
- United States Food and Drug Administration (FDA)
 - blood collection establishment regulations 66–70
 - defective product reporting 72
 - global regulation 78
 - guidance documents 68–69
 - hospital transfusion services regulation 71–72
 - inspections 69
 - iron depletion regulations 58–59
 - Office of Blood Research and Review 68
 - reportable deviations 69
 - screening regulations 39–40, 41–42
 - service error reporting 71–72
- United States (US)
 - albumin regulations 223–224
 - blood collection establishments regulations 66–70
 - blood services organizations 12
 - blood testing requirements 37, 38, 39–40, 41–42
 - hospital transfusion services regulations 70–73
- universal leukocyte reduction 11
- upper airway procedures
 - plasma administration 468
 - platelet administration 469
- upper gastrointestinal bleeding, red blood cell administration 321
- uremia, thrombocytopenia 394
- urological tissue engineering 658–659
- uromodulin (Tamm–Horsfall protein) 97
- US Code of Federal Regulations (CFR) 67–68
- UV-A *see* ultraviolet A
- UV-C *see* ultraviolet C
- vaccinations
 - gene therapy 644
 - health emergencies 23
 - hemophilia 432
- vaccine-induced immune thrombotic thrombocytopenia (VITT) 417
- valganciclovir 192
- validation, virus reduction/removal 219–220
- vapor heat, virus inactivation 220
- variant Creutzfeld–Jakob disease (vCJD) 11, 31, 529–531
- vascular access
 - apheresis 252, 260, 265
 - central venous catheters 260, 466–467, 469
- vascular tissue allografts 676–677
- vascular tissue engineering 656–657
- vasculitis, apheresis 272
- vasculitis with hepatitis B-associated polyarteritis nodosa, apheresis 272
- vasovagal reactions, blood donation 50
- vCJD *see* variant Creutzfeld–Jakob disease
- vectors, gene therapy 643–644
- VEL blood group system 117
- venipuncture 307
- VER 117
- VGCC *see* voltage-gated calcium channel
- VGKC *see* voltage-gated potassium channel
- Vibrio* Spp, ABO type 86
- vinca alkaloids 410
- viral infections
 - chikungunya 518
 - cytomegalovirus 46, 192, 519
 - dengue 517–518
 - ebola 520–521
 - Epstein–Barr virus 519
 - hepatitis A 9–10, 47, 192, 507–508
 - hepatitis B 9–10, 43–44, 192, 272, 507–508
 - hepatitis C 511–513
 - hepatitis D 513–514
 - hepatitis E 514
 - hepatitis F 515
 - hepatitis C 44
 - herpesviruses 519
 - HIV 10, 31, 43, 96, 192

- viral infections (*cont'd*)
 - HIV-1 515–516
 - HIV-2 516–517
 - HTLV 44, 516–517
 - human T-cell lymphotropic virus 44
 - lymphatic choriomeningitis 521
 - neutropenia-causing 192
 - pandemic influenza 521
 - Parvovirus B19 47, 96, 333–334, 519–520
 - T-cell therapy 637–638
 - transfusion-transmitted 507–522
 - TT virus 521
 - West Nile virus 45, 518
 - Zika virus 45
- viral testing
 - cytomegalovirus 46
 - hepatitis A 47
 - hepatitis B 43–44
 - hepatitis C 44
 - human T-cell lymphotropic virus 44
 - Parvovirus B19 47
 - source plasma donors 34–36
 - West Nile virus 45
 - Zika virus 45
- viral-inactivated purified fibrinogen concentrate 211
- virus inactivation, plasma 220–221
- virus reduction, plasma 219–220
- viscoelastic assays, point-of-care 459
- vital sign measurement, donors 32
- vitamin K 446–447
 - adverse reactions 447
 - dosing 447
 - indications 447
 - manufacturing 447
 - storage 447
- vitamin K antagonists (VKA), reversal 443–447
- VITT *see* vaccine-induced immune thrombotic thrombocytopenia
- VKA *see* vitamin K antagonists
- voltage-gated calcium channel (VGCC) autoantibodies, apheresis 267
- voltage-gated potassium channel (VGKC) antibody diseases, apheresis 269
- volume reduction, platelets 186, 485
- von Hippel–Landau protein (pVHL) 136–137
- von Willebrand disease (vWD) 434–437
 - acquired 451–452
 - classification 434–436
 - clinical features 434
 - diagnosis 434–436
 - treatment 436–437
- von Willebrand factor (vWF) 436–437
 - cryoprecipitate transfusion 210–211
 - in plasma 201–202
 - platelet formation 160–161
 - purification 232–233
- von Willebrand factor-cleaving protease 201
- vWD *see* von Willebrand disease
- WAIHA *see* warm autoimmune hemolytic anemia
- Walter, C. 9
- warfarin effect, plasma transfusion 214
- warm autoimmune hemolytic anemia (WAIHA) 106–107, 346–351
 - clinical features 348–349
 - DAT positive without hemolytic anemia 349
 - DAT-negative 349
 - epidemiology 346
 - pathophysiology 346–348
 - prognosis 351
 - treatment 349–351
- warming blood 313
- WAS *see* Wiskott Aldrich syndrome
- washed cell salvage 300–301
- washing
 - platelets 186
 - red blood cells 155
- WB *see* whole blood
- WBDPs *see* whole blood derived platelets
- WBIT *see* wrong blood in tube
- weak D phenotype 101–102, 103, 105–106
- weak subtypes, ABO system 82–83
- West Nile virus (WNV) 45, 518
- WFH *see* World Federation of Hemophilia
- white blood cells 188–248
 - apheresis 195, 286
 - granulocytes 193–199
 - leukocytapheresis 286
 - neutrophils 188–193
- WHO *see* World Health Organization
- whole blood derived platelets (WBDPs)
 - collection 32
 - separation 33
- whole blood (WB)
 - administration
 - burn patients 480
 - trauma patients 480
 - collection 32
 - pathogen reduced, function tests 496–498
- Wilson Disease, apheresis 273
- Wiskott Aldrich syndrome (WAS) 161
 - gene therapy 644
- WNV *see* West Nile virus
- World Federation of Hemophilia (WFH) 78
- World Health Organization (WHO)
 - blood and blood component safety programs 74–75
 - Blood Regulators Network 75
 - blood screening requirements 39
 - blood services recommendations 12–13
 - Expert Committee on Biological Standardization 75
- World War II 9
- wrong blood in tube (WBIT) 306
- xenotransplantation, Sd^a antigen 98
- Xg blood group system 114
- XK protein 111–112
- Zarxio *see* filgrastim-sndz
- ZFNs *see* zinc finger nucleases
- Ziextenzo *see* pegfilgrastim-bmez
- Zika virus (ZIKV) 45
- ZIKV *see* Zika virus
- zinc finger nucleases (ZFNs) 644

